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PRECLINICAL DEVELOPMENT OF THERAPEUTIC STRATEGIES AGAINST
TRIPLE-NEGATIVE AND INFLAMMATORY BREAST CANCER
Angie Marie Torres-Adorno, B.S.
Advisory Professor: Naoto T. Ueno, M.D., Ph.D.

Triple-negative (TNBC) and inflammatory (IBC) breast cancer are the most aggressive
forms of breast cancer, accounting for 20% and 10% of cancer-related deaths, respectively.
Among IBC cases, 30% are additionally classified with TNBC molecular pathology, a diagnosis
that significantly worsens patient’s prognosis. The current lack of TNBC and IBC molecular
understanding prevents the development of effective therapeutic strategies. To identify effective
treatments, we explored aberrant apoptosis pathways and cell membrane fluidity as novel
therapeutic targets.

We first identified an effective therapeutic strategy against TNBC and IBC by proapoptotic protein NOXA-mediated inhibition of the anti-apoptotic protein MCL1 following
inhibition of histone deacetylases (HDAC) in combination with inhibition of the oncogenic
MEK pathway. In breast cancer patients, low NOXA/high MCL1 tumor expression is indeed
associated to poor survival outcomes, supporting the induction of NOXA expression, and
subsequent inhibition of MCL1, for the treatment against TNBC and IBC.

Secondly, we investigated the role of an anti-inflammatory and non-toxic
polyunsaturated fatty acid, eicosapentaenoic acid (EPA), for the development of a treatment
strategy against TNBC and IBC. Through a synthetic-lethal siRNA high-throughput screen we
identified inhibition of EPHA2, an oncogenic protein specifically associated to poor survival in
vi

TNBC patients, to be the top candidate that enhanced EPA cytotoxicity against TNBC and IBC
cells. Though functional assays, we identified combination EPA and EPHA2-inhibition to be an
effective therapeutic strategy involving the induction of cell death via modulation of cell
membrane fluidity by ABCA1 inhibition-mediated intracellular cholesterol accumulation in
triple-negative IBC cells.

In summary, here we provide robust preclinical evidence that supports the Phase I
clinical development of combination HDAC and MEK inhibitors, and of EPA and EPHA2inhibition, for the treatment of patients with TNBC and IBC.
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CHAPTER 1: INTRODUCTION

1.1 Breast cancer
1.1.1 Breast cancer epidemiology
In the United States, breast cancer is the most commonly diagnosed cancer in women,
accounting for 252,710 new cases in 2017 (1). Breast cancer is also the second most common
cause of cancer related death in women, with an estimated 40,610 deaths, or 15%, in 2017
(Figure 1) (1). While breast cancer death rates have decreased by 32% over the last 90 years,
thanks to the continued research and development of therapeutic strategies, its incidence has
seen a rise of about 20%, demonstrating an urgent need to continue exploring new therapeutic
approaches with increased efficacy against breast cancer.

Figure 1. Estimated breast cancer incidence and death rates for 2017.

1.1.2 Breast cancer molecular subtypes
Breast cancer is characterized by its heterogeneity among patients. Breast cancer
subtyping is often performed by the assessment of expression of three main proteins: estrogen
1

receptor (ER), progesterone receptor (PgR), and HER2/neu (receptor tyrosine-protein kinase
erbB-2, HER2). Gene expression-based techniques, in particular by the use of the PAM50 gene
set (2), are often used to identify breast cancer subtypes, although subtyping by use of protein
panels of immunohistochemical markers are still widely used in the clinic. Unfortunately,
discrepancies between these two subtyping methods exist (2), which leads to different treatment
decisions. There are four major intrinsic molecular subtypes of breast cancer, based on their
respective protein and gene signatures: Luminal A, Luminal B, HER2-enriched, and Triplenegative (basal-like) (3, 4). Luminal A subtype is characterized by its hormone receptor (ER,
92% agreement between PAM50 and IHC subtyping; and/or PgR, 94% agreement) positivity,
together with negativity of the HER2 growth receptor, and low levels of the proliferation marker
Ki67 (5). Luminal A breast cancers tend to have the best prognosis due to their inhibited growth
rate (6). Luminal B breast cancer subtype is similarly hormone receptor positive (ER, 92%
agreement; and/or PgR, 74% agreement), but could be either HER2 receptor positive or
negative, with high levels of Ki67 (7). Luminal B breast cancers tend to grow at a faster rate
compared to Luminal A, together with worse prognosis (6). HER2-enriched breast cancers are
positive for the HER2 receptor, but negative for hormone receptors (77% agreement) (8). This
subtype tends to grow at a faster rate compared to luminal subtypes, therefore having a
worsened prognosis (9), but HER2 targeted treatment strategies are often highly effective (10).
Triple-negative breast cancers are negative for all three growth receptors: hormone (ER and
PgR), and HER2 (5, 9), are mainly comprised of basal-like (57% agreement) and HER2 (30%
agreement) subtypes. Even with its lack of receptor expression, this subtype is characterized by
its high rate of growth, migration, and invasion compared to all other breast cancer subtypes
(11).

2

1.2 Triple-negative breast cancer
Triple-negative breast cancer (TNBC or TN), representing 10-17% of all breast
carcinomas, is diagnosed molecularly in terms of its negative ER, PgR, and HER2 receptor
status, and is associated with lower survival and a higher risk of local and regional relapse,
compared to hormone (ER/PgR)-positive and HER2-positive breast cancers (12, 13). TNBC
tumors are classified as basal-like subtypes, due to their expression profiles resembling those of
basal epithelial cells with a high expression of basal markers (e.g., keratins 5, 6, 14, 17, EGFR)
and proliferation-related genes (5). Approximately 60 to 90 % of basal tumors are triplenegative cases, allowing for the association of basal and TNBC tumors as similar entities (14).
This subtype is common in younger women carrying BRCA1 and TP53 gene mutations, being
even more common among African-American women and pre-menopausal individuals (3, 15).
TNBC is a highly heterogeneous disease characterized by its strong metastatic potential and
poor prognosis, which can be further sub-classified based by its canonical pathways among the
subtypes: basal-like1, basal-like 2, immunomodulatory, mesenchymal-like, mesenchymal stemlike, and luminal androgen receptor (16).

1.3 Inflammatory breast cancer
Inflammatory breast cancer (IBC) is a rare clinical diagnosis representing 1-5% of all
breast carcinomas, but disproportionately associated with 10% of breast cancer related deaths
(17, 18). Instead of the appearance of a distinct lump, the IBC clinical onset consists of redness
(erythema), swelling (edema), pitted skin (peau d’orange), or inverted nipple of the breast,
caused by the buildup of lymph in the ducts and skin as a result of cancer cells blockage (tumor
emboli) of the lymph vessels, preventing normal lymph flow (Figure 2) (19). Similar to TNBC,
IBC is characterized by its strong metastatic potential and associated poor prognosis. Among all
3

breast cancer molecular subtypes, IBC has a worse prognosis when compared to noninflammatory forms of breast cancer (non-IBC) cases (20). TNBC accounts for about 30% of
IBCs molecular subtype, which is a significantly higher proportion when compared to nonTNBCs (17, 21). There is a theory in the breast cancer field that this high percentage of TNBC
may be the reason that IBC has been associated with a more aggressive clinical course and
decreased breast cancer-specific and overall survival (22, 23).

Figure 2. Clinical appearance of an Inflammatory
Breast Cancer patient.

1.4 Standard of care for triple negative and inflammatory breast cancer
Among the triple-negative status of TNBC, conventional targeted therapies are ineffective,
with the current standard care of cytotoxic chemotherapy followed by surgery displaying
moderate efficacy with a 5-year overall survival of approximately 80% (24). Although TNBC
has been observed to be sensitive to conventional chemotherapies, several studies have shown
that the poor prognosis for TNBC is mainly due to the lack of additional treatment options
available (10).

4

The standard treatment for IBC consists of chemotherapies known as anthracyclines, and
targeted therapies when applicable (HER2-positive cases), followed by surgery and radiation
therapy, in this specific order. As the most aggressive form of breast cancer, even after
multidisciplinary treatment, the 5-year overall survival of IBC is only 30% to 50% (25, 26). Due
to the lack of patient samples for this rare disease, molecular studies have failed to identify
specific molecular signatures that could predict treatment response, survival, or therapeutic
targets (27-29). Nevertheless, despite the relatively small sample sizes available, a gene
expression profile study of IBC patients in correlation with response to neoadjuvant
chemotherapy was able to show that response to neoadjuvant chemotherapy in IBC was linked
to immunity-related processes, providing evidence for a possible mechanism to predict
pathological complete response (30). There has been an improvement in IBC diagnosis and
staging due to significant advances in imaging, such as digital mammography, magnetic
resonance imaging, and positron emission tomography-computed tomography, among others,
increasing survival to approximately 40%, which is still a relatively low rate (31, 32). Continued
investigation into significant molecular characteristics as well as effective therapeutic strategies
remains a necessity.

1.4.1 Experimental therapeutic approaches for TNBC and IBC
Multiple experimental approaches are currently being explored for the treatment of these
aggressive types of breast cancer, triple-negative and inflammatory. In IBC, molecular targets in
vasculolymphatic processes (angiogenesis, lymphangiogenesis, and vasculogenesis) have
demonstrated greater potential than in non-IBC (33, 34). Although loss of E-cadherin is a
hallmark of epithelial-to-mesenchymal transition and may correlate with the promotion of
metastasis, paradoxically, E-cadherin is overexpressed in IBC through an unknown mechanism
5

(35, 36). Others are currently investigating whether targeting EGFR and HER2 (which are
overexpressed in about 60% of IBC tumors and associated with rapid tumor growth and
metastasis via activation of the AKT and ERK/MEK oncogenic pathways), may aid in the
development of effective targeted therapeutic strategies in IBC (37-39). In our research group,
inhibition of histone deacetylases (HDACs) has additionally been explored for its effects on
HER2/EGFR inhibitors as a therapeutic approach against HER2-overexpressing IBC (40).

In TNBC, new approaches involving the use of antiangiogenic agents as neoadjuvants to
pre-operative chemotherapies have demonstrated improved patient prognosis and likelihood of
pathological complete response (pCR), compared to patients with other breast cancer subtypes
(41). Large biomarker programs are ongoing to identify TNBC subgroups that could have an
increased benefit from such therapies (42). Targeted therapies involving inhibition of HDACs,
mammalian target of rapamycin (mTOR), and growth factors such as fibroblast, epithelial and
vascular endothelial growth factor receptors are currently being clinically tested in TNBC,
showing insufficient improvement in patients’ outcomes (43-46).

1.5 Limitations with current strategies and gaps in knowledge
To date, IBC and TNBC are challenges for both patients and biomedical professionals due
to their poor prognoses and lack of significantly effective treatments or targeted therapy options,
contributing to high mortality rates compared to other breast cancer subtypes. The main
challenges with the current therapeutic strategies reside in the acquired resistance, recurrence,
and high level of invasion/metastasis at time of diagnosis on IBC and TNBC patients (47). To
address these issues, combination therapies, together with in-depth analysis of potential
biomarkers associated with disease aggressiveness or treatment response in patients, have been
6

in development, but these still have not provided evidence of complete effectiveness against
TNBC and IBC (29, 48). Therefore, it is essential to continue exploring potential combinational
treatment strategies as well as molecular and physiological cellular mechanisms that are
determinants of disease aggressiveness and response to treatments, potentially providing the
identification of therapeutic strategies that are effective for the treatment of IBC and TNBC.

1.6 Goal of the project
In this project, our goal is to discover new physiological and molecular mechanisms
contributing to TNBC and IBC aggressiveness and to identify novel combination therapy
strategies with enhanced efficacy (Figure 3). Therefore, we hypothesized that combination

Figure 3. Illustrated diagram of major topics of interest to be evaluated in this study.
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therapy strategies targeting tumor promoting factors would have enhanced efficacy against
TNBC and IBC compared to monotherapies. First, we evaluated molecular mechanisms
associated with the epigenetic modulation of Histone Deacetylases (HDACs), which are critical
regulators of gene expression commonly disrupted in cancer cells, including IBC and TNBC,
which are associated with cancer progression. We evaluated HDACs by use of an HDAC
inhibitor, entinostat, in association with apoptosis induction in TNBC and IBC.

Additionally, we investigated the use of an anti-inflammatory omega-3 polyunsaturated
fatty acid, eicosapentaenoic acid (EPA), as a potential strategy for the therapy of TNBC and
IBC. Inflammation plays an important role in tumor development and progression, representing
an important factor to target for effective cancer therapies. EPA has been linked to
modifications in cell membrane physiology as well as destabilization of intracellular pathways
associated with inflammation, which subsequently contributes to increased cytotoxic properties
in cancer cells and decreased tumor proliferation.

My in-depth evaluation of the association of HDACs and inflammation contributions to
IBC and TNBC cancer progression, as well as the efficacy of their targeting to apoptosis
induction, provided new knowledge for TNBC and IBC development. Additionally, the
evidence discovered through these studies served as a translational base supporting the
development of clinical trials against the two most aggressive types of breast cancer.
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CHAPTER 2: MATERIALS AND METHODS

2.1 Breast cancer patient tumor expression analysis
We analyzed the World IBC Consortium dataset that contains Affymetrix GeneChip
(HGU133 series) RNA hybridization profiles of 389 breast cancer patient samples, which
include 137 IBC cases and 105 TNBC cases, as previously described (49). Briefly, the IBC
cases included locally advanced (American Joint Committee on Cancer [AJCC] stage III) and
metastatic (AJCC stage IV) cases. The non-IBC cases included both early-stage disease (AJCC
stages I and II) and advanced-stage disease (locally advanced, AJCC stage III; and metastatic,
AJCC stage IV). Information on data processing, normalization, and analyses has been
previously reported (30). Regression models were used to delineate changes in NOXA/PMAIP1
(204286_s_at) and MCL1 (214056_at) gene expression. P-values, corrected for multiple
comparisons, were considered significant only if the false discovery rate was smaller than 0.25.

We utilized the BreastMark algorithm to identify associations with disease progression
and EPHA2 expression. Developed by the Molecular Therapeutics for Cancer, Ireland (MTCI)
at Dublin University (Glasnevin, Dublin) (50), this algorithm integrates mRNA gene expression
and survival data for evaluation of genes that are significantly associated with disease-free
survival (DFS) in breast cancer and its molecular subtypes. The algorithm contains gene
expression data from 26 datasets on 12 different microarray platforms corresponding to
approximately 17,000 genes in up to 4,738 samples, as well as detailed clinical data, allowing
for correlation of subject outcome with gene expression, as previously described (50). We
specifically evaluated the EPHA2 mRNA expression in basal (TNBC) tumor subtypes as
determined by the PAM50 molecular classifier (11).
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2.2 Cell lines
Human breast cancer cell lines BT-549, SUM185PE, MDA-MB-157, MDA-MB-453,
MDA-MB-231, HCC70, MDA-MB-468, MDA-MB-436, HCC1806, HCC1937, and Hs578T
were purchased in 2011 from American Type Culture Collection (ATCC, Manassas, VA);
SUM149PT, SUM159PT, and SUM190PT cells in 2011 from Asterand Bioscience, Inc.
(Detroit, MI); and HCC3153 in 2013 from UT Southwestern Medical Center (Dallas, TX).
KPL-4 cells were a kind gift in 2008 from Dr. Junichi Kurebayashi (Kawasaki Medical School,
Kawasaki, Japan), IBC-3 cells from Dr. Wendy Woodward, and BCX010 cells were generously
donated for this study by Dr. Funda Meric-Bernstam (The University of Texas MD Anderson
Cancer Center, Houston, TX). HCC1806, MDA-MB-231, MDA-MB-468, MDA-MB-436,
MDA-MB-157, MDA-MB-453, Hs578T, HCC70, and KPL-4 cells were maintained in
Dulbecco’s modified Eagle’s medium/F12 medium (GIBCO) supplemented with fetal bovine
serum (FBS; 10%) and penicillin-streptomycin (100 units/mL). SUM149PT, SUM190PT,
SUM185PE, SUM159PT, BCX010 and IBC-3 cells were maintained in F12 medium (GIBCO)
supplemented with FBS (5%), penicillin-streptomycin (100 units/mL), insulin (5 μg/mL), and
hydrocortisone (1 μg/mL). BT-549, HCC1937, and HCC3153 cells were maintained in RPMI
1640 medium (GIBCO) supplemented with FBS (10%) and penicillin-streptomycin (100
units/mL). SUM190PT, SUM149PT, IBC-3, BCX010 and KPL-4 are IBC cell lines (51, 52).
All cell lines were passaged for up to 20 times after thawing. Details about molecular receptor
status and TNBC subtype classification can be found in Table 1 (16). All used cell lines were
authenticated by genotyping through MD Anderson Cancer Center’s Characterized Cell Line
Core Facility, and routinely tested for mycoplasma contamination using MycoAlert™ (Lonza,
Allendale, NJ).
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Table 1. Breast cancer cell lines’ molecular receptor status and TNBC subtype
classification. Sources for molecular receptor status, TNBC subtypes, and IBC classification:
Asterand Bioscience, Inc. ER: estrogen receptor; PR: progesterone receptor; HER2: Human
epidermal growth factor receptor 2; BL: basal-like; M: mesenchymal; LAR: luminal androgen
receptor; +, positive status; -, negative status; *, IBC diagnosis; N/A, not applicable.
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2.3 Reagents and antibodies
Entinostat (SNDX-275) was provided by Syndax Pharmaceuticals, Inc. Pimasertib
(AS703026) was provided by EMD Serono, Inc. We obtained anti-NOXA (EMD Millipore,
Billerica, MA), anti-MCL1 (R&D Systems, Minneapolis, MN, or Thermo Fisher Scientific,
Waltham, MA), anti-PUMA, anti-BIM, anti-BAK, anti-BAX, anti-cleaved caspase 3, anticleaved caspase 9, and anti-Ki67 (Cell Signaling Technology, Beverly, MA), anti-α-tubulin
(clone B-5-1-2; Sigma-Aldrich), and anti-horseradish peroxidase-conjugated antibodies
(Thermo Scientific, Rockford, IL). The following small interfering RNAs (siRNAs) targeting
NOXA were purchased from Sigma-Aldrich (St Louis, MO) and used for depletion of NOXA:
SASI_Hs01_00136187, SASI_Hs01_00136188, SASI_Hs01_00136189, and
SASI_Hs01_00136192. Knockdown efficacy of pooled siRNAs was tested by immunoblotting.
Scrambled siRNA was purchased from Thermo Fisher Scientific (ON-TARGETplus nontargeting control pool, catalog number D-001810). The following expression vectors were
purchased from GeneCopoeia (Rockville, MD): OmicsLink pReveiver-M77 expression clone
NOXA (EX-I0491-M77), MCL1 (EX-G0192-M77), and Control (EX-EGFP-M77).

Eicosapentaenoic acid (EPA) and cholesterol powder bio-reagent suitable for cell culture
were purchased from Sigma-Aldrich (St Louis, MO). Doxycycline was purchased from
Research Products International (Mount Prospect, IL). Dasatinib was purchased from Selleck
Chemicals (Houston, TX). Methyl-β-cyclodextrin (MβCD) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). All in vitro assays were performed after treatments for 24-48
hour with EPA (IC20: 50 µM), doxycycline (Dox, 1-3 µg/mL), dasatinib (IC20: 0.3 µM),
cholesterol (1 mM), Methyl-β-cyclodextrin (4 mM), or rosuvastatin (2.5 µM).
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We obtained anti-EPHA2, anti-phosphorylated EPHA2, anti-SRC, anti-phosphorylated
SRC, anti-cleaved caspase 3, and anti-Ki67 (Cell Signaling Technology, Beverly, MA), antiIgG-PE, anti-EPHA2-PE, anti-IgG-APC, anti-EPHA2-APC, anti-ABCA1 (Novus Biologicals,
Littleton, CO), anti-SREBP2 (R&D Systems, Minneapolis, MN), anti-HMGCR (Thermo Fisher
Scientific, Waltham, MA), anti-LDLR (Abcam, Cambridge, MA), anti-α-tubulin, anti-β-actin
(Sigma-Aldrich), and anti-horseradish peroxidase-conjugated antibodies (Thermo Scientific,
Rockford, IL). The following small interfering RNAs (siRNAs) targeting EPHA2 and ABCA1
were purchased from Sigma-Aldrich (St Louis, MO) and used for depletion of EPHA2:
SASI_Hs01_00026514, SASI_Hs01_00026516, and SASI_Hs01_00026517; and ABCA1:
SASI_Hs01_00129036, SASI_Hs01_00129036, and SASI_Hs01_00129038. Knockdown
efficacy of pooled siRNAs was tested by immunoblotting. Scrambled siRNA control was
purchased from Thermo Fisher Scientific (ON-TARGETplus non-targeting control pool, catalog
number D-001810). The following expression vectors were purchased: Human EPHA2 and
control (pLOC-GFP) (GE Healthcare Biosciences, Pittsburgh, PA), pCMV3-untagged
expression clone ABCA1 (HG11924-UT), and control (pCMV3-GFP) (Sino Biologicals Inc.,
North Wales, PA). These were transfected into TN-IBC cells following manufacturer’s
instructions.

2.4 Western blot analysis
Total protein extracts were prepared using cold lysis buffer (50 mM Tris-HCl, pH 7.4,
1% NP-40, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1 mM EDTA, and
phosphatase/protease inhibitors). Equal amounts of protein (15 to 20 μg for each sample) were
resolved by SDS-PAGE gel. Membranes were incubated with antibodies of interest overnight.
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Signals were detected using an Odyssey IR imaging system (LI-COR Biosciences, Lincoln, NE)
or chemiluminescent substrates (Thermo Scientific).

2.5 Quantitative real-time PCR
Total RNA was purified using the PureLink® RNA Mini Kit (Invitrogen), and real-time
qRT-PCR was performed using the iScriptTM One-Step RT-PCR Kit with SYBR® Green (BioRad, Hercules, CA) according to the manufacturer’s instructions, after treatment with entinostat
(1 µM). Equal amounts of total RNA (15 ng for each sample) were mixed, and target genes
were amplified with a specific primer set using the CFX96TouchTM Real-Time PCR Detection
System (Bio-Rad). The following primers (Sigma-Aldrich) were used for detection of NOXA:
5’-CCAGCAGAGCTGGAAGTCGAGTG-’3 (forward), and 5’TGCAGTCAGGTTCCTGAGCAGAAG-’3 (reverse). 7SL scRNA (NR_002715.1) levels were
used as an endogenous control; the following primers were used: 5’ATCGGGTGTCCGCACTAAGTT-’3 (forward), and 5’-CAGCACGGGAGTTTTGACCT-’3
(reverse). The real-time PCR data were analyzed by comparative threshold cycle method using
the iCycler CFX96 analyzer software (Bio-Rad).

2.6 Annexin V apoptosis assays
Apoptosis was measured with PE or APC Annexin V supplemented with 7AAD (BD
Biosciences, San Jose, CA), or with Annexin V-green (Essen Bioscience, Ann Arbor, MI).
Briefly, after treatment for 48 hours, apoptosis induction was quantified by flow cytometry
analysis (after incubation with Annexin V-PE or -APC), or by IncuCyte® live cell analysis
system (after incubation with Annexin V-green), according to the manufacturer’s instructions.
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2.7 In vivo xenograft animal models
Animal studies were approved by the IACUC and MD Anderson Animal Care and Use
Committee. For the HDAC and MEK inhibitors studies, female athymic homozygous nu/nu
mice, age 4-6 weeks old, were purchased from MD Anderson’s Department of Experimental
Radiation Oncology for the SUM190PT, SUM149PT, and MDA-MB-231 xenograft
experiments. Mice were housed under pathogen-free conditions and treated in accordance with
NIH guidelines. To establish breast cancer xenografts, SUM190PT (2 × 106 cells/100 µL),
SUM149PT (5 × 106 cells/100 µL), or MDA-MB-231 (5 × 106 cells/100 µL) cell suspensions
were injected into one site in the abdominal mammary fat pad of each mouse. We observed
100% tumor incidence for all three cell lines. Drug treatments via daily oral gavage started
when the tumors were approximately 100-150 mm3. We used 0.5% (w/v) methyl cellulose 400
solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) plus 0.25% Tween 20 as drugs
vehicle. Tumor volume [V = 0.5 × (L × W2)] and body weight were measured twice weekly.
Drug treatment continued for 28 days (SUM190PT), 56 days (SUM149PT), or 42 days (MDAMB-231), and then mice were euthanized. Tumor tissues were collected, sectioned and
preserved both by flash freezing and paraffin block embedding for further analysis.

To study the antitumor efficacy of EPA therapy animal studies, female immunodeficient
NOD SCID gamma (NSG) mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Laboratory, Bar
Harbor, ME), aged 4-6 weeks, were purchased from MD Anderson’s Department of
Experimental Radiation Oncology for xenograft experiments. Mice were housed under
pathogen-free conditions and treated in accordance with NIH guidelines. To establish breast
cancer xenografts, SUM149PT (5 × 105 cells/100 µL), or BCX010 (5 × 105 cells/100 µL) cell
suspensions were injected into one site in the fourth inguinal mammary fat pad of each mouse.
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We observed 100% tumor incidence for all cell lines. Drug treatments started when the tumors
were approximately 100-150 mm3; at this point mice were randomized among experimental
treatment groups (N = 9 to 10 per group). EPA was administered ad libitum through customized
AIN-76A mice diets (Research Diets Inc., New Brunswick, NJ) containing the FDA-approved
Vascepa (purified EPA) at doses equivalent to the maximum (4 g) and half (2 g) human daily
recommended doses; equivalent to 6 g and 3 g of Vascepa per kg of mice diet verified by
chromatographic fatty acid analysis. These doses are equivalent to mice EPA daily intakes of
0.8 g/kg and 0.4 g/kg, considering an average daily food intake of 3.5 g, and average mice
weight of 25 g. Doxycycline (2 mg/mL) water containing 2% sucrose was provided ad libitum
to induce shRNA expression in pTRIPZ-transduced tumor cell lines implanted in mice.
Dasatinib (2.5 mg/kg) treatment was provided via intraperitoneal injection six days a week. We
used sterilized water solution plus 30% PEG 400 (Thermo Fisher Scientific), 1% Tween 80, and
4% dimethyl sulfoxide (Sigma-Aldrich) as drug vehicle. Tumor volume [V = 0.5 × (L × W2)]
and body weight were measured twice weekly. Mice tolerated all treatments with no significant
adverse events or change in body weight noted. Drug treatments continued until primary tumor
reached 1,500 mm3 or mice morbidity. Mice were then euthanized and tissues harvested for
molecular analysis.

2.8 In vitro cell proliferation assay
For cell proliferation experiments in vitro, we utilized sulforhodamine B (SRB) (Sigma
Aldrich), or CellTiter-Blue (Promega, Madison, WI) colorimetric protein staining assays were
performed according to the manufacturer’s instructions. The percentages of surviving cells from
each group were estimated relative to the control culture, which was defined as 100% viability.
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2.9 Soft agar assay
Cells (2103 cells/well) were resuspended in 2 mL of 0.4% agarose solution in
DMEM/F12 or F12 medium and overlaid onto the bottom agar layer (0.8%) in 6-well plates.
The plates were incubated for 21 days with drugs, and colonies were stained with 200 μL of
MTT solution (1 mg/ml) for 2 hours. The stained colonies greater than 80 m in diameter were
counted using the GelCount colony-counting system (Oxford Optronix, UK) according to the
manufacturer’s instructions. Means and standard deviations were calculated on the basis of the
colony counts from triplicate wells

2.10 Co-immunoprecipitation
Cultured SUM190PT and SUM149PT cells were collected after described treatments,
and were washed with pre-chilled PBS, followed by cell lysing with a cold non-denaturing lysis
buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl2, 1
mM EDTA, and phosphatase and protease inhibitors). To immunoprecipitate MCL1 proteins,
lysate (500 μg) was mixed with 5 μg MCL1 antibody (R&D Systems) for 2 hours at 4°C with
rotation. Protein G Sepharose 4 Fast Flow beads (GE Healthcare, Marlborough, MA) were
added to the antigen–antibody complex and incubated for 1 hour at 4°C with rotation. Beads
were recovered by low-speed centrifugation and washed with lysis buffer. LDS sample buffer
and sample reducing agent (Novex Life Technologies, NuPAGE®) were added to each sample
and incubated at 70°C for 10 minutes, centrifuged, and subjected to SDS-PAGE. After
appropriate separation, gels were transferred and analyzed for co-immunoprecipitation using
standard immunoblotting techniques as described previously
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2.11 Immunohistochemistry (IHC)
Tumor tissues were fixed in neutral-buffered formalin and embedded in paraffin.
Sections (5 µm each) were prepared using a microtome, mounted on slides, deparaffinized in
xylene, rehydrated in graded alcohols, and washed in distilled water. Antigens were retrieved by
boiling the sections in 10 mM citric acid (pH 6.0) for 40 min. Endogenous peroxidases were
quenched by incubation in 3% H2O2 for 10 min at room temperature. The slides were washed
three times with phosphate-buffered saline (PBS) and blocked for 30 min with 10% normal goat
serum in 1% bovine serum albumin/PBS. The slides were then exposed previously described
antibodies. Immunostained slides were scanned with a high definition microscope, and the
images were captured at a magnification of 50× and stored using ImageScope software
according to the manufacturer’s instructions. Immunostained slides were evaluated by
densitometry using the ImageJ software.

2.12 TUNEL staining
DNA fragmentation in mouse tissue samples was measured by in situ terminal
deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) using the DeadEnd
TUNEL kit (Promega, Madison, WI). The mouse tumor xenografts’ TUNEL-positive cells were
evaluated in 3 randomized fields at 20x magnification, and the average was expressed as the
number of apoptotic cells for each sample.

2.13 Chromatin Immunoprecipitation
Acetylation levels of the NOXA gene promoter following entinostat treatment (1 µM, 48
hours) were measured by chromatin immunoprecipitation (ChIP) assay using the Simple ChIP
Enzymatic Chromatin IP Kit (magnetic beads) following manufacturer’s protocol (Cell
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Signaling Technology, Beverly, MA). Briefly, untreated and entinostat treated SUM149PT and
SUM190PT cells (4x106 cells per sample) were nuclease digested and sonicated (3 cycles of 30
seconds) to shear DNA to approximately 150-900 bp in size. Sonicated chromatin samples were
incubated with antibodies against acetylated-lysine, Histone H3 as positive control, or normal
rabbit IgG as negative control (Cell Signaling Technology, Beverly, MA), overnight at 4°C with
rotation. Two percent was used of total genomic DNA from nuclear extracts as input. Purified
immunoprecipitation and input DNA were used as templates for RT-qPCR with the following
primers to amplify the NOXA promoter region (Forward: 5’-AGTAATTTCGGGGCCGAGC-3’
and Reverse: 5’- GGCGTTATGGGAGCGGAC-3’). Quantification of DNA by RT-qPCR was
done following manufacturer’s protocol.

2.14 Synthetic-lethal siRNA screen
To identify a targetable candidate that would complement the antitumor effect of EPA, we
performed a high-throughput, synthetic lethal siRNA screen using a kinome library containing
939 druggable genes in the TN-IBC cell line SUM149PT, in combination with EPA treatment.
A reverse transfection method was performed in which 45 nM siRNA is initially allowed to
complex in an assay plate with DharmaFECT-2 transfection reagent (0.07 µL, GE Dharmacon,
Lafayette, CO) for 30 minutes, followed by addition of 30 µL of solution containing 750
cells/condition, after which the plates were incubated for 48 hours at 37°C in a 5% CO2
atmosphere. After incubation, cells were treated with EPA (IC50: 50 µM) and incubated for an
additional 72 hours at 37°C in a 5% CO2 atmosphere. OTP3 and TOX were identified as optimal
negative and positive siRNA transfection controls, respectively. After treatment, assay plates
were imaged (IN-Cell Analyzer 6000, GE Healthcare Life Sciences) and cells were assessed for
viability as determined after incubation with CellTiter-Blue® (Promega Corporation, Madison,
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WI) and quantification of fluorescence intensity (PHERAstar FS Plate Reader, BMG Labtech
Inc., Cary, NC). Data were normalized to the values for untreated controls, and statistical
measures were applied to remove assay variability as previously described (53). The siRNA
screen data have been deposited in Gene Expression Omnibus (GEO) with accession number:
GSE102057.

2.15 Cell lines with doxycycline-inducible genes
We established doxycycline-inducible non-coding-shRNA or EPHA2-shRNA
SUM149PT and BCX010 cell lines using the following inducible expression vectors: pTRIPZ
non-targeting (RHS4743) and pTRIPZ-human-EPHA2 (V3THS_322576) inducible lentiviral
shRNA vectors (GE Dharmacon), both containing a red fluorescent protein (RFP) tag. Briefly,
lentivirus was produced using manufacturer’s instructions, concentrated with PEG-it virus
precipitation solution (System Biosciences, Palo Alto, CA) and applied to cultures of
SUM149PT and BCX010 for 24 hours. Positive transductions were selected with puromycin (5
µg/mL), followed by flow cytometry to isolate RFP-positive cells upon doxycycline treatment.
EPHA2 knockdown was validated by western blot and flow cytometry following 24 hours
doxycycline treatment.

2.16 Xenograft tumor cell sorting
Tumors containing RFP-positive cells following Dox treatment were mechanically
homogenized prior to incubation in 3 mL collagenase A (1 mg/mL) for 10 minutes. The
digested solution was neutralized with an equal volume of 5% FBS in phosphate-buffered saline
solution (PBS), then filtered (40 µm) and centrifuged at 400 x g for 5 minutes. Following
centrifugation, the supernatant was discarded and the cell pellet was resuspended in 1 mL red
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blood cell lysis buffer (StemCell Technologies, Cambridge, MA), and subjected to
centrifugation again. After centrifugation, cells were resuspended in 2% FBS (500 µL) in PBS,
counted, and incubated with anti-IgG-APC or anti-EPHA2-APC antibody (5 µL / 1 × 106 cells,
Novus Biologicals) for 20 minutes, followed by centrifugation and two washings with 2% FBS
(1 mL) in PBS wash. Cells were finally resuspended in 2% FBS (500 µL) in PBS, and SYTOX®
blue (1:500, Life Technologies, Carlsbad, CA) was added to stain dead cells before flow
cytometry analysis. EPHA2 protein expression was quantified in the RFP-induced tumor cell
population.

2.17 Membrane fluidity assay
Membrane fluidity was determined by using the lipophilic fluorescent probe Laurdan (6dodecanoyl-2-dimethylaminonaphthalene, Thermo Fisher Scientific). Briefly, following
treatment for 24 or 48 hours, the cell membranes were extracted by lysis with hypotonic buffer
(0.2 mM EDTA, 1 mM NaHCO3) containing protease/phosphatase inhibitors, and cells were
allowed to swell for 30 minutes, followed by brief sonication. Remaining intact cells were
removed by centrifugation at 800 x g for 10 minutes. The supernatant was collected and
subjected to ultra-centrifugation at 100,000 x g for 45 minutes, yielding a crude total membrane
pellet; this pellet was re-suspended in buffer (10 mM TRIS and anti-protease cocktail, in PBS)
before addition of the Laurdan fluorescent probe and incubation for 1 hour at 37°C. After
incubation, the fluorescence measurements were performed using a Quanta-Master model QM3SS (Photon Technology International) cuvette-based fluorescence spectrometer. Using a Peltier
TE temperature controller, the sample was held at a constant of 37°C and fluorescence
measurements (excitation 350 nm; emission wavelengths, 440 and 490 nm) were performed.
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Data were collected and analyzed using Felix 32 software. General polarization (GP, a measure
of fluidity) of the membrane was determined by the following equation:

𝐺𝑃 =

(𝐼𝐹440𝑛𝑚 − 𝐼𝐹490𝑛𝑚)
(𝐼𝐹440𝑛𝑚 + 𝐼𝐹490𝑛𝑚)

Where IF440nm and IF490nm represent the fluorescence intensity detected at the 440 nm
and 490 nm wavelengths, respectively. Higher GP values are indicative of increased
polarization, or rigidity. Conversely, lower GP values represent a less rigid, more fluid state.

2.18 Membrane fluidity imaging
Following 24 to 48 hours of treatment, cells were washed with PBS and fixed with 4%
formaldehyde for 20-30 minutes. Fixed cells were then incubated with 5 µM C-laurdan for 20
minutes at room temperature. Following incubation, the cells were washed 3x with PBS, and
mounted to a coverslip with Prolong Gold. Cell were imaged via confocal microscopy on a
Nikon A1R with spectral imaging at 100x with an excitation of 405 nm. The emission was
collected in two bands: 433-463 nm (IF440) and 473-503 nm (IF490). MatLab was used to
calculate the 2D GP map, where the GP for each pixel was calculated from a ratio of the two
fluorescence channels, as described (54). Briefly, each image was binned (2 x 2), backgroundsubtracted, and threshold applied to keep only pixels with intensities greater than three standard
deviations of the background value in both channels. The GP image was calculated for each
pixel using the equation above.

2.19 Fatty acid analysis
Total lipids from mouse diet pellets, tumor tissues and serum samples were extracted by
the method of Folch et al. (55, 56). Total phospholipids were separated by thin-layer
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chromatography on silica gel 60 plates using chloroform/methanol/acetic acid/water (90:8:1:0.8,
v/v) as the developing solvent. Isolated lipid fractions were methylated, and the resultant fatty
acid methyl esters were analyzed by gas chromatography/mass spectrometry as described
elsewhere (57).

2.20 Mass spectrometry EPA analysis
Phospholipids were extracted from membranes of treated cells for quantifications of
lipid profiles. Briefly, to extract membrane phospholipids, cell pellets were resuspended in
chilled PBS (50 µL), and cold 100% methanol (100 µL) was added into 20 µL aliquots of the
cell homogenates. After mixing by vortex, samples were subjected to centrifugation at 3,000
rpm for 5 minutes at 4°C. Each supernatant was transferred into a new tube, and analyzed by
liquid chromatography-mass spectrometry (LC-MS; 1290 LC System and 6460 Triple
Quadruple MS, Agilent, Santa Clara, CA). For the LC instrument, a C18 high-performance
liquid chromatography (HPLC) column (Phenomenex Kinetex, Torrance, CA) was utilized
using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in acetonitrile as
mobile phase B. The MS instrument was utilized in positive-ion electrospray mode, and ion
scan mode was set at MS2=184 (phosphatidylcholine) and MS2=264 (ceramide). Output data
were processed using the MassHunter WorkStation Software (Agilent).

2.21 Cholesterol quantification
Total cellular membrane fractions were extracted from treated cells using the Subcellular
Protein Fractionation assay (Thermo Scientific) according to the manufacturer’s instructions.
After the cell membrane fraction was extracted, cholesterol concentration was quantified by
Amplex® Red Cholesterol Assay (Thermo Fisher Scientific) according to manufacturer’s
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instructions. Briefly, extracted membrane fraction (20 µg) was diluted in reaction buffer (50
µL; 0.1 M potassium phosphate, pH 7.4, 0.05 M NaCl, 5 mM cholic acid, 0.1% Triton® X-100
in deionized water), Amplex Red working solution (50 µL; 2 U/mL horseradish peroxidase, 2
U/mL cholesterol oxidase, 0.2 U/mL cholesterol esterase, 0.75 μL Amplex Red reagent solution,
0.5 μL HRP solution, 0.5 μL cholesterol oxidase solution, and 0.05 μL cholesterol esterase
solution in reaction buffer) was added and the tubes were incubated at 37°C for 30 minutes.
After incubation, fluorescence was measured in a fluorescence plate reader using excitation at
570 nm and emission detection at 590 nm.

2.22 Statistical analysis
For experimental outcomes, descriptive statistics (mean and standard error of the mean)
were summarized for each group. An analysis of variance (ANOVA) model was used to
compare the mean outcome values among the tested groups. The log-rank test was used to
compare survival curves. Statistical analyses were performed using an unpaired t-test with Prism
version 5 (GraphPad Software, La Jolla, CA). P values of < 0.05 were considered statistically
significant. Synthetic-lethal siRNA screen data analysis was carried out using t-test followed by
Beta-Uniform mixture model to adjust p-values in statistical computing software R (version
3.0.1) (58).
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CHAPTER 3: IDENTIFICATION OF AN HDAC AND MEK INHIBITORS
COMBINATION STRATEGY AGAINST TNBC AND IBC

This chapter is based upon the manuscript by: A. M. Torres-Adorno, J. Lee, T. Kogawa,
P. Ordentlich, D. Tripathy, B. Lim, N. T. Ueno, Histone deacetylase inhibitor enhances the
efficacy of MEK inhibitor through NOXA-mediated MCL1 degradation in triple-negative and
inflammatory breast cancer. Clin Cancer Res, (2017) (59). According to the American
Association for Cancer Research, no permission is necessary for use of materials from this
publication by authors on doctoral dissertation work.

3.1 Introduction
3.1.1 Epigenetic modulation in cancer
Epigenetic modulation in malignancies often silences genes that regulate proliferation
and metastasis, thereby contributing to tumor aggressiveness. Histone deacetylases (HDACs)
are critical regulators of gene expression; they do so through enzymatic removal of acetyl
groups from histones that prevents DNA access to the transcriptional machinery that promotes
gene expression (Figure 4). Aberrant expression of HDACs, leading to tumorigenesis, is
observed in multiple types of human cancers.

Figure 4. Diagram of histone deacetylases activity in the removal of
acetyl groups from histones and silencing of gene expression.

25

3.1.2 Histone deacetylase inhibitors
In the last decade, multiple HDAC inhibitors have been developed as anti-cancer drugs
and have shown anti-tumor action (60). Entinostat (formerly MS-275, Syndax Pharmaceuticals,
Inc., Waltham, MA), a selective class I HDAC inhibitor with low toxicity to normal cells, is a
synthetic benzamide derivative that can reduce the proliferation of cancer cells and tumors
xenografts in a variety of human cancers (61). Entinostat also displayed preliminary therapeutic
efficacy in a randomized phase II clinical trials for ER-positive breast cancer patients (62).

Although it is not known from available clinical trials whether entinostat can induce the
expression of pro-apoptotic proteins in IBC and TNBC tumors, recent preclinical evidence
demonstrated entinostat-induced expression of the pro-apoptotic BIM protein in IBC and TNBC
(40), suggesting the induction of apoptosis as a major mechanism of tumor suppression.

3.1.3 The BCL-2 family of proteins and apoptosis regulation
The Bcl-2 family of proteins are critical modulators of apoptosis, acting immediately
upstream of irreversible cellular damage, where anti-apoptotic and pro-apoptotic family
members control the release of apoptogenic factors from mitochondria (63). NOXA, a Bcl-2
homology domain 3 (BH3)-only pro-apoptotic protein, is epigenetically silenced by histone
acetylation in cancer (64, 65). Independently, NOXA displays weak pro-apoptotic activity,
however it is a crucial modulator of cell death thought its ability to interact with the pro-survival
Bcl-2 molecule MCL1 (induced myeloid leukemia cell differentiation protein 1). MCL1 is
commonly amplified in TNBC and has been shown to be an adverse prognostic factor for
survival (66). Degradation of MCL1 during cell death is uniquely associated with the formation
of an MCL1/NOXA complex, while stabilization of MCL1 is associated with its ability to bind
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other BH3-only members (i.e. PUMA or BIM) (67-69). Alternatively, MCL1 protein can be
stabilized through the activation of the mitogen-activated protein kinase/extracellular signalregulated kinase (ERK) signaling pathway, which promotes survival and drug resistance in
cancer cells (70-72). Since MCL1 is crucial to cancer cell survival, drugs that target the ERK
pathway may have therapeutic value through their ability to reduce MCL1 expression.

3.1.4 Oncogenic MEK/ERK pathway and TNBC
ERK is an important therapeutic target in TNBC; high ERK expression correlates with
shorter patient overall survival (73). While ERK inhibitors have not been effective in clinical
testing, compounds that inhibit MEK (an upstream activator of ERK) including selumetinib
(formerly AZD6244) (74, 75), and the more potent compound pimasertib (formerly AS703026,
EMD Serono, Inc., Rockland, MA) (76, 77) have displayed clinical activity in phase II trials for
melanoma and ovarian cancer (78, 79).

3.1.5 Gap in knowledge
While the effectiveness of these HDAC and MEK inhibiting compounds remains to be
clinically established in breast cancer, it have been previously shown their potential for
preventing metastasis in preclinical xenograft models of TNBC (80). As such, there is a need to
identify the efficacy of a combination therapy utilizing ERK and HDAC inhibitors, potentially
due to their parallel inhibitory effects on MCL1 protein levels in TNBC and IBC.
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3.2 Results
3.2.1 NOXA and MCL1 expression are molecularly and clinically relevant to entinostat
and pimasertib treatment in IBC and TNBC.
Previous studies reported entinostat-induced expression of the pro-apoptotic protein BIM
in TNBC and IBC cell lines, suggesting the induction of apoptosis as a major mechanism of
tumor suppression (40). To identify apoptosis-related molecular changes induced by entinostat
in TNBC and IBC cells following treatment, we performed a quantitative PCR array with 28
apoptosis-related probes on two established cell lines: SUM190PT (IBC), and SUM149PT
(IBC-TNBC), chosen because of their IBC and TNBC status. We found that NOXA/PMAIP1
(also called phorbol-12-myristate-13-acetate-induced protein 1, or PMAIP1) was among the top
upregulated apoptosis-related mRNAs after 48 hours of entinostat treatment on both cell lines
(Table 2), consistent with previous observations in acute myeloid leukemia (81). Because
NOXA promotes intrinsic apoptosis through proteasomal degradation of the anti-apoptotic
protein MCL1, while the ERK pathway is known to support MCL1’s stabilization, we next
analyzed the effect of entinostat on the phosphorylation/activation of ERK (p-ERK) in IBC
(IBC3, KPL-4, SUM149PT, and SUM190PT) and non-IBC (BT-474, MDA-MD-231, MDAMB-468, and SKBR3) cell lines. After 48 hours of treatment, entinostat induced p-ERK
expression is IBC (3 out of 4) and TNBC (MDA-MB-468) while no inducing effect was
observed on another major cancer-related pathway, AKT, among the tested cell lines (Figure 5).
These results suggest p-ERK could act as a stabilizer for MCL1 in IBC and TNBC, representing
a potential target that could enhance apoptosis in combination with entinostat treatment.

Based on this observation, we pursued further studies addressing how NOXA/MCL1
expression may contribute to the therapeutic efficacy of combining entinostat and an ERK
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pathway inhibitor in IBC and TNBC. We first determined the clinical relevance of NOXA and
MCL1 expression levels to breast cancer patient outcome. We analyzed a previously published
cDNA microarray dataset of breast cancer patient samples, which contains IBC (35%) and nonIBC (65%; 27% TNBC) cases (49). Kaplan-Meier survival analysis revealed that low MCL1
mRNA expression levels within patient tumors significantly correlated with longer patient
overall survival (OS) and distant metastasis-free survival (DMFS) than high MCL1 mRNA
levels (P = 0.017 and 0.0041, respectively) (Figure 6A, D). Conversely, high NOXA expression
was associated with longer OS (a nearly significant difference, P = 0.052), but not DMFS
(nonsignificant, P = 0.64) in this cohort (Figure 6B, E). When stratified by both MCL1 and
NOXA tumor expression, significantly longer OS and DMFS were seen in patients with low
MCL1/high NOXA expression than in patients with high MCL1/low NOXA expression (P =
0.0008 and 0.02, respectively) (Figure 6C, F).

Next, we investigated NOXA and MCL1 in vitro. Using quantitative real-time PCR
analysis, and chromatin immunoprecipitation (ChIP), we confirmed increased NOXA mRNA
expression associated with NOXA gene promoter acetylation levels following entinostat
treatment (1 µM) in SUM190PT and, to a lesser degree, SUM149PT cells, compared to the
untreated control (Figure 7). To further confirm this finding, we screened other IBC (KPL-4
and IBC-3) and TNBC (SUM159PT, BT-549, SUM185PE, MDA-MB-157, MDA-MB-453,
MDA-MB-231, HCC70, MDA-MB-468, MDA-MB-436, HCC1806, HCC1937, HCC3153, and
Hs578T) cell lines (Figure 8). Compared to untreated cell lines, NOXA mRNA was induced by
entinostat treatment in 65% (11 of 17) of the IBC and TNBC cell lines tested. Immunoblotting
analysis was performed on all cell lines to identify relationships between protein expression
levels of NOXA and MCL1 after entinostat treatment (data shown for 12 cell lines, Figure 9).
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Table 2. Effect of entinostat on the expression of apoptosis-related gene pathways. The
expression profile of apoptosis-related genes for SUM149PT and SUM190PT cell lines after
entinostat treatment for 48 hours. Results are represented as the fold-change of the log2 values of
entinostat treated cells in comparison to the values observed in non-treated cells. GENE-E
software (The Broad Institute, Cambridge, MA) was utilized for heat map visualization of gene
expression data.
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Figure 5. Entinostat induces increased phosphorylation/activation of the pro-survival ERK
pathway in IBC cell lines. A, IBC and non-IBC cell lines were treated with various concentrations of
entinostat, and ERK, p-ERK, AKT, and p-AKT protein expression was determined by immunoblotting
analysis. B, SUM190PT and SUM149PT cells were treated with the ERK pathway inhibitor pimasertib
or the AKT pathway inhibitor MK-2206 to confirm increased activation of p-ERK after entinostat
treatment. Total AKT and ERK expression was used as a protein loading control.
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Figure 6. High MCL1/low NOXA co-expression is associated with poor outcome in breast cancer
patients. Kaplan-Meier survival curves for overall survival (OS) and distant metastasis-free survival
(DMFS) of breast cancer patients from the IBC World Consortium dataset, correlated to NOXA and
MCL1 tumor mRNA levels. The log-rank test was used to compare survival curves for high and low
MCL1 (A, D), high and low NOXA (B, E), and high or low MCL1 in correlation with low or high
NOXA (C, F). The initial numbers of patients at risk in each group are indicated in the key.
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Figure 7. Increased NOXA gene promoter acetylation levels following entinostat treatment.
SUM149PT and SUM190PT cell lines were treated with entinostat (1 µM) for 48 hours, and NOXA gene
promoter acetylation was assessed by ChIP assay with an acetylated-lysine antibody. H3 and IgG
antibodies were used as positive and negative ChIP controls, respectively. NOXA promoter DNA
expression was determined by RT-qPCR; Percent of NOXA-promoter DNA from input samples is
presented. *, P < 0.05.
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Figure 8. Entinostat treatment selectively increases expression of NOXA mRNA in TNBC and IBC
cell lines. NOXA mRNA levels were analyzed in multiple TNBC and IBC cell lines using quantitative
real-time PCR after 48 hours of treatment with entinostat (1 µM), compared to the untreated control.
Data were pooled from three independent experiments.
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Figure 9. Basal MCL1 protein expression is present in most TNBC and IBC cell lines. NOXA and
MCL1 protein expression levels were determined in multiple TNBC and IBC cell lines by
immunoblotting analysis after 48 hours of treatment with entinostat (1 µM). Pixel density of proteins
was quantified for each condition, and ratios of protein/tubulin are shown above the blots. DetectableMCL1-expressing cell lines were defined as those with pixel density of MCL1/tubulin ≥ 0.4, the
average density of MCL1 among all tested cell lines. Tubulin expression was used as a protein loading
control.
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NOXA protein expression did not positively correlate with increased NOXA mRNA expression
levels, possibly due to the short protein half-life of NOXA through proteasome-dependent
degradation (82). We also identified detectable levels of MCL1 protein expression in 80% of
cell lines, as defined by MCL1/tubulin pixel density ≥ 0.4 (the average MCL1 pixel density
among all cell lines), and observed induction of MCL1 protein expression in multiple cell lines
following entinostat treatment. Together with our preliminary data demonstrating that entinostat
mediated p-ERK expression (Figure 5), the changes in protein levels of MCL1 suggest the
stabilization of MCL1 through p-ERK pathway activation in TNBC and IBC cells.

3.2.2 Entinostat and pimasertib combination therapy synergize to inhibit the growth of
aggressive breast cancer cells that overexpress NOXA after entinostat treatment.
As a monotherapy for TNBC and IBC, the efficacy of entinostat may be hindered due to
the induction of MCL1 through p-ERK activation. Thus, we hypothesized that addition of the
MEK inhibitor pimasertib may potentiate cellular cytotoxicity of entinostat by simultaneously
blocking ERK activation. Synergistic killing by the combination therapy was observed in 12 of
17 IBC and TNBC cell lines tested (representative data shown for three cell lines, Figure 10A),
with response predominantly correlated to each cell line’s level of NOXA mRNA induction after
entinostat treatment (representative data for combination index (CI) shown for eight cell lines,
Figure 11). Sixty percent of cell lines responding to combination therapy had high basal MCL1
protein levels (MCL1/tubulin pixel density ≥ average, 0.4), while the other 40% of responding
cell lines displayed synergistic cell killing despite low MCL1 expression, which may be
associated with the induced levels of NOXA, as observed in previously. Therefore, the
effectiveness of combination treatment was correlated to NOXA-mRNA-inducible cell lines,
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potentially inducing apoptosis by enhanced targeting of MCL1, providing a mechanism that
could circumvent the problems associated with monotherapy.

To determine cell death induction levels after treatment, we next analyzed the effect of
entinostat and pimasertib on apoptosis after dose response experiments of clinically achievable
(≤ 1 µmol/L) doses. The SUM190PT and SUM149PT cell lines were selected for further
analysis based on their TNBC and/or IBC status, as well as their significant induction of
NOXA-mRNA following entinostat treatment. The HCC1806 TNBC cell line was selected as a
negative control based on its lack of entinostat-mediated NOXA-mRNA induction and apparent
resistance to treatment. As shown in Figure 10B, single entinostat or pimasertib treatment
induced apoptosis by 10% and 9%, respectively, in SUM190PT cells and by 16% and 6% in
SUM149PT cells, compared with the control (untreated cells). However, combination treatment
significantly increased the proportion of apoptotic cells by 30% in SUM190PT and SUM149PT
cells compared with the control. The TNBC cell line HCC1806 did not respond to single or
combination treatment, which correlates to its inability to express NOXA following entinostat
treatment. Collectively, these data suggest that the combination of entinostat and pimasertib is
most effective in TNBC and IBC cell lines in which NOXA can be induced.
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Figure 10. Entinostat and pimasertib combination treatment enhanced cell death in IBC and
TNBC cell lines that overexpressed NOXA after entinostat treatment. SUM190PT, SUM149PT, and
HCC1806 cells were treated with clinically achievable (≤ 1 µmol/L) doses, representative data shown for
entinostat (1 µM) and pimasertib (1 µM) for 48-72 hours. The IC50 values of entinostat were determined
for SUM190PT, SUM149PT, and HCC1806 cell lines to be 0.6 µM, 0.3 µM, and 0.9 µM, respectively;
the IC50 values of pimasertib were 1.9 µM, 0.6 µM, and 2.5 µM, respectively. Cell proliferation and
apoptosis were measured by SRB staining (A) and Annexin V-PE staining (B), respectively. Data were
pooled from three independent experiments and presented as mean ± SEM. *, P < 0.05; **, P < 0.001;
***, P < 0.0001.
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Figure 11. TNBC and IBC cell lines overexpressing NOXA after entinostat treatment exhibit
synergy of combination treatment with pimasertib. The entinostat and pimasertib dose–effect for
combination treatment (1 µM, 1:1 ratio) synergism was calculated using CalcuSyn software (Biosoft,
Cambridge, UK). A fractional index (Fa), or the fraction of cells affected by the dose, of 1.0 indicates
100% growth inhibition. Combination index (CI) is a quantitative measure of the degree of drug
interaction: <0.9 = synergy, 0.9 - 1.1 = additive effect, > 1.1 = no synergy.
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As the efficacy of the combination therapy correlated with the induction of pro-apoptotic
NOXA, we next assessed the broader spectrum of proteins involved during apoptosis. We
initially assessed the effect of single and combination therapy on the expression of downstream
pathway members BIM, BAK, BAX, PUMA and caspase-9 (Figure 12). After 48 hours of
treatment, we found that the anti-apoptotic MCL1 protein was reduced, while the NOXAregulated, pro-apoptotic BCL-2 proteins BIM, BAX and BAK were elevated in two IBC cell
lines. As expected, we detected increased levels of cleaved caspase-9, which indicates the
induction of apoptosis in these cell lines. As a negative control, we did not observed alterations
in MCL1, NOXA or cleaved caspase-9 in the therapeutically insensitive HCC1806 cells (Figure
13), consistent with this cell line’s observed lack of apoptosis induction following combination
treatment (Figure 10B). PUMA expression was not consistently altered after single or
combination treatments, suggesting that it may not play a main role in MCL1 degradation.
These data suggest that NOXA-based regulation of apoptosis may be responsible for therapeutic
efficacy in TNBC and IBC.

Because NOXA can bind to and enhance the degradation of MCL1 protein (69), and we
had observed induction of NOXA expression and increased apoptosis in cell lines sensitive to
combination therapy, we hypothesized that NOXA-MCL1 binding may contribute to cell death
with our therapy. To confirm whether NOXA bound MCL1 in our system, we performed an
MCL1 immunoprecipitation assay on cell lines following treatment. Following MCL1
precipitation, we were able to detect elevated NOXA protein by immunoblotting analysis in two
cell lines treated with both entinostat and pimasertib (Figure 14). These results suggest that our
combination therapy leads to enhanced apoptosis in TNBC and IBC cells by reducing MCL1
expression potentially through NOXA-mediated degradation of MCL1.
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Figure 12. Mitochondrial apoptosis activated following combination therapy. MCL1, NOXA,
PUMA, and mitochondrial apoptosis-related proteins BIM, BAX, BAK, and cleaved caspase-9 were
examined through immunoblotting analysis. Pixel density of proteins was quantified for each
condition, and the ratios of protein/tubulin or treatment/control are shown next to the blots; tubulin
expression was used as a protein loading control.
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Figure 13. Low-NOXA-inducible HCC1806 cell line did activated mitochondrial
apoptosis after entinostat and pimasertib single or combination treatments. Expression
levels of NOXA, MCL1, and apoptosis-related protein cleaved caspase-9 were determined
through immunoblotting analysis in the low-NOXA-inducible HCC1806 cell line after 48
hours of treatment with entinostat (1 µM) and pimasertib (1 µM). Tubulin expression was
used as a protein loading control.
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Figure 14. NOXA binds to MCL1 following combination entinostat and pimasertib treatment.
NOXA/MCL1 binding on SUM190PT and SUM149PT cells was determined after entinostat (1 µM)
and pimasertib (1 µM) individual and combination treatment by immunoprecipitation (IP) using antiMCL1 antibody and immunoblotting with anti-NOXA antibody. After-IP samples were also blotted
with NOXA antibody as an IP control. Pixel density of proteins was quantified for each condition,
and the ratios of protein/tubulin or treatment/control are shown next to the blots; tubulin expression
was used as a protein loading control.
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3.2.3 NOXA and MCL1 play important roles in regulation of sensitization of IBC and
TNBC cells to entinostat and pimasertib treatment.
To determine whether NOXA is a critical component in defining the therapeutic efficacy
of entinostat and pimasertib, we functionally silenced NOXA mRNA expression and assessed
the response of SUM190PT and SUM149PT cells to treatment (Figure 15A). When treated with
entinostat, NOXA-silenced SUM190PT and SUM149PT cells did not display altered activation
of caspase-3, however the loss of NOXA expression hindered the cytotoxic effects of entinostat
compared to scrambled siRNA control (P < 0.05, and P < 0.005, respectively) (Figure 15A-B).
The unaltered induction of cleaved caspase-3 upon siNOXA inhibition is probably due to the
high levels of NOXA mRNA that are still induced after entinostat treatment of siNOXAtransfected SUM190PT and SUM149PT cells (5- and 3-fold increase, Figure 15A), permitting
apoptosis. These results suggest a role for NOXA in enabling cytotoxicity after entinostat
treatment.

In a reverse-complementary approach, we assessed whether transient over-expression of
NOXA could modulate cells’ response in combination with pimasertib in the treatment-sensitive
SUM190PT and SUM149PT cells, or the treatment-resistant HCC1806 cells, which lack
entinostat-mediated NOXA mRNA induction (Figure 15C). Following overexpression of
NOXA and pimasertib treatment, SUM190PT and SUM149PT cells had significant inhibition of
cell proliferation compared to untreated cells (P < 0.0001, and P < 0.005, respectively) (Figure
15D), further supporting the significance of NOXA mediating MCL1 degradation and
enhancing pimasertib treatment. In contrast, HCC1806 cells had increased resistance to
pimasertib treatment after NOXA overexpression. These findings suggest that the HCC1806
resistant cell line could have an alternative mechanism by which it is able to override NOXA
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activity, possibly due to expression of other anti-apoptotic proteins, or activation of cell survival
pathways, avoiding NOXA-mediated apoptosis.

As we have demonstrated that NOXA can affect overall protein levels of MCL1 leading
to altered drug sensitivity in IBC and TNBC cells, we next assessed whether alteration of MCL1
could similarly modulate the therapeutic action of our rationalized combination treatment.
Following transient MCL1 expression, entinostat and pimasertib single and combination
treatments were tested in SUM190PT and SUM149PT cells (Figure 16A, B). Overexpression of
MCL1 significantly reversed the sensitivity of SUM190PT and SUM149PT cells to entinostat
single (P < 0.05) and combination treatments (P < 0.0001). Conversely, when we treated
SUM190PT and SUM149PT cells with a highly selective MCL1 inhibitor, UMI-77, in
combination with pimasertib, we observed synergistic growth inhibition (CI values < 0.6 and
0.9, respectively; data not shown), accompanied by a significant induction of apoptosis
compared to untreated control cells (P < 0.05) (Figure 16C, D). These data indicate that MCL1
is critical for the resistance of IBC and TNBC cells to treatment, and suggests a synergistic antiproliferative combination of pimasertib with inhibitors of MCL1 expression, such as through
entinostat-mediated NOXA degradation of MCL1.
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Figure 15. NOXA expression plays an important role in the regulation of sensitization of TNBC
and IBC cells to treatment. SUM190PT and SUM149PT cells were transfected with NOXA (siNOXA)
or Scrambled (siSCR) siRNA through electroporation. Knockdown of NOXA mRNA and induction of
apoptosis as measured by cleaved caspase-3 after siRNA inhibition were confirmed by quantitative RTPCR and immunoblotting analysis (A), respectively, after entinostat treatment for 24 and 72 hours. Cell
proliferation after siRNA and entinostat treatment was measured by SRB staining after 72 hours (B).
SUM190PT, SUM149PT, and HCC1806 cells were transfected with either a NOXA-expressing vector or
empty control vector by electroporation. Expression of NOXA, as well as MCL1, was analyzed by
immunoblotting analysis 72 hours after transfection (C). Pixel density of MCL1 was quantified for each
condition, and the ratios of MCL1/tubulin are shown above the blots; tubulin expression was used as a
protein loading control. Proliferation of cells with NOXA overexpression in response to treatment with
pimasertib (2.5 µM) was determined by SRB staining after 72 hours (D). Data were pooled from three
independent experiments and presented as mean ± SEM. *, P < 0.05; **, P < 0.005; ***, P < 0.0001.
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Figure 16. MCL1 protein expression and activity have a significant role in the sensitivity of TNBC
and IBC cells to pimasertib and entinostat combination treatment. SUM190PT and SUM149PT cells
were transfected with either MCL1-expressing or empty control vectors by electroporation (A, B).
Induced expression of MCL1 protein was confirmed by immunoblotting analysis. The ability of MCL1
overexpression to induce cell proliferation after entinostat (5 µM) and pimasertib (5 µM) single and
combination treatments was measured by SRB staining after 72 hours. Cell proliferation (C) and
apoptosis (D) were determined by SRB staining and Annexin V-PE staining, respectively, in SUM190PT
and SUM149PT cells after inhibition of MCL1 by the small molecule inhibitor UMI-77 (0.3 µM and 5
µM, respectively) in combination with pimasertib (1 µM). Data were pooled from three independent
experiments and presented as mean ± SEM. Tubulin expression was used as a protein loading control. *,
P < 0.05; **, P < 0.001; ***, P < 0.0001.
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3.2.4 Entinostat and pimasertib combination treatment suppresses tumorigenic potential
in vitro and in vivo tumor growth in xenograft models of aggressive breast cancer.
Prior to the in vivo drug testing, we first assessed whether the combination of entinostat
and pimasertib could affect the ability of TNBC and IBC cells to form anchorage-independent
tumor spheroids in vitro. Preliminary studies indicated that the IC50 doses for both drugs were
too toxic in this experimental setting to allow any colony growth (data not shown). Therefore,
we selected lower doses than the IC50 for both entinostat and pimasertib. Combination treatment
significantly reduced the number of colonies formed by SUM190PT and SUM149PT cells
compared to single-drug treatments (P < 0.05), whereas in the treatment-resistant HCC1806
cells entinostat did not affected tumorigenicity, and pimasertib and combination treatment only
mildly inhibited colony formation (Figure 17).

After confirming reduced cell proliferation and anchorage-independent growth following
entinostat and pimasertib combination treatment in vitro, we next determined whether these two
drugs could inhibit tumor growth in preclinical xenograft animal models of TNBC and IBC.
Mice (n = 10 to 12 per group) were treated with optimized doses of entinostat (20 mg/kg/day for
SUM190PT, 5 mg/kg/day for SUM149PT), pimasertib (30 mg/kg/day for SUM190PT, 0.5
mg/kg/day for SUM149PT), or a combination of both drugs. When compared to mice treated
with vehicle control, combination-treatment mice displayed a significant reduction in tumor
growth rate by 79% (P<0.0001) and 65% (P<0.001) in SUM190PT and SUM149PT cells,
respectively (Figure 18). Of importance, while high dose single treatment of entinostat
(20mg/kg) or pimasertib (30mg/kg) significantly inhibited tumor growth (Figure 18 and Figure
19A), at lower doses the combination treatment out performed single treatment in SUM149PT
(Figure 18) and MDA-MB-231 xenografts (Figure 19B). Mice tolerated all treatments with no
48

significant change in body weight noted (Figure 20). Immunostaining for markers of
proliferation and cell death in SUM190PT, SUM149PT, and MDA-MB-231 primary tumors
identified, as expected, a reduction of Ki67-positivity and an increase in TUNEL or cleaved
caspase-3 staining in tumors receiving combination treatment (Figure 21 and Figure 19B).
Lastly, after entinostat and pimasertib combination treatment protein lysate expression of tumor
samples from SUM190PT and SUM149PT xenograft models revealed higher protein expression
of NOXA and its downstream marker of mitochondrial cell death, cleaved caspase-9, together
with decreased expression of MCL1 (average protein expression quantified relative to tubulin
loading control, n = 5 tumors per treatment group, Figure 22 A, B). Together, these results
suggest increased apoptosis consistent with TUNEL staining following entinostat and
pimasertib combination treatment through mediation of NOXA expression and subsequent
degradation of MCL1 enhanced by pimasertib in TNBC and IBC.

Figure 17. Entinostat and pimasertib combination treatment inhibits colony formation in vitro.
SUM190PT, SUM149PT and HCC1806 cell lines were treated with entinostat (0.01 and 0.05 µM,
respectively) and/or pimasertib (0.01 and 0.05 µM, respectively) and allowed to grow in an anchorageindependent environment for 2-3 weeks; clonal growth was measured at the treatment endpoint by
colony formation (A). Data were pooled from three independent experiments and presented as mean ±
SEM. *, P < 0.05; **, P < 0.001; ***, P < 0.0001.

49

Figure 18. Entinostat and pimasertib combination treatment inhibits tumor growth in vivo.
Tumor volume measurements for SUM190PT and SUM149PT tumor xenograft-bearing mice
(n=12/group and 10/group, respectively) treated via oral gavage daily for up to 2 months with vehicle,
entinostat (20 or 5 mg/kg), and/or pimasertib (30 or 0.5 mg/kg). *, P < 0.05; **, P < 0.001; ***, P <
0.0001.
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Figure 19. Higher and lower doses of entinostat and pimasertib combination treatment induce
tumor regression in IBC and TNBC xenograft models. A, SUM149PT tumor-bearing mice
(n=12/group) were treated with high doses of entinostat (20 mg/kg/day) and/or pimasertib (30
mg/kg/day), similarly to the experiments in SUM190PT xenografts (Figure 6C), via oral gavage daily for
6 weeks. B, Low doses of entinostat (2.5 mg/kg/day) and pimasertib (2 mg/kg/day) were tested on a third
TNBC xenograft model, MDA-MB-231 (n=9/group) via oral gavage daily for 6 weeks.
Paraformaldehyde-fixed paraffin tumor sections from MDA-MB-231 tumor-bearing mice from each
treatment group were immunostained with anti-Ki-67 or anti-cleaved caspase-3 antibodies (bottom bar
graphs). Images from IHC staining were converted by ImageJ software to accomplish quantification of
Ki-67 and cleaved caspase-3 expression. Quantification of IHC staining is represented as mean ± SEM.
*, P<0.05; **, P<0.001; ***, P<0.0001.
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Figure 20. No toxicity was observed after entinostat and pimasertib single and
combination treatments in vivo. Evaluation of average mice body weights during
animal experiments. Measurements were taken twice a week for each treatment group in
SUM190PT (A) and SUM149PT (B) tumor-bearing mice.
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Figure 21. Combination entinostat and pimasertib therapy inhibits proliferation, and promotes
apoptosis, in vivo. Immunohistochemistry (IHC) staining from SUM190PT and SUM149PT tumor
xenografts treated with vehicle or the indicated drugs. Paraformaldehyde-fixed paraffin sections
were incubated with (A) anti-Ki-67 antibody, and (B) TUNEL staining was performed.
Representative images of 5 IHC staining experiments are illustrated. Magnification, 20x. The images
were converted by ImageJ software to accomplish quantification of Ki-67 and TUNEL expression.
Quantification of IHC staining is represented as mean ± SEM. *, P < 0.05; **, P < 0.001; ***, P <
0.0001.
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Figure 22. Entinostat and pimasertib combination treatment promotes NOXAmediated apoptosis and decreased expression of MCL1. Protein expression (represented
as mean ± SEM) relative to loading control after immunoblotting analysis of NOXA, MCL1,
and cleaved caspase-9 expression in protein lysates of five representative tumor samples
from each treatment group of mice bearing SUM190PT or SUM149PT tumors. Tubulin
expression was used as a protein loading control. Pixel density of protein bands was
quantified for each condition using ImageJ software. *, P < 0.05; **, P < 0.001; ***, P <
0.0001.
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3.3 Discussion
Our study has revealed that combination of entinostat and pimasertib synergistically act
to reduce tumorigenic potential, proliferation, and in vivo growth of tumor using preclinical
models of TNBC and IBC. The effectiveness of this treatment was significantly associated to
the ability of tumors to induce mRNA expression of NOXA, a member of the Bcl-2 family of
apoptosis-regulating proteins, in 65% of TNBC and IBC cell lines following entinostat
treatment, leading to enhanced degradation of the anti-apoptotic protein MCL1 in IBC and
TNBC. Further, in our retrospective genomic analyses on an extensive clinical cohort of breast
cancer patients, we were able to associate high-MCL1/low-NOXA tumor expression in breast
tumors with worse OS and DMFS outcomes when compared with low-MCL1/high-NOXAexpressing tumors, which supports the translational potential for targeting these molecules in the
clinical setting.

Several studies have demonstrated that entinostat induces apoptosis by expression of
death receptor tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and
transcriptional upregulation of pro-apoptotic Bcl-2 proteins BIM and NOXA in acute myeloid
leukemia (81) and in HER2-overexpressing breast cancers (40), supporting chemosensitization
(83). Here, we identified selective induction of NOXA mRNA expression after entinostat
treatment in a subset of IBC and TNBC cell lines, which often correlated with increased protein
expression of MCL1 as well as p-ERK, a known stabilizer of MCL1. Thus, our data suggest that
besides the induction of NOXA after single entinostat treatment, additional p-ERK induction
could play a role in the stabilization of anti-apoptotic MCL1, supporting our strategy of testing
an ERK pathway inhibitor, pimasertib, as a synergistic partner.
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The interaction between MCL1 and NOXA contributing to apoptosis has been
previously demonstrated, whereby MCL1 is recruited from the cytosol into the mitochondria by
NOXA promoting BIM release from MCL1 sequestration, which initiates MCL1
phosphorylation and subsequent ubiquitination triggering proteasome-mediated degradation (68,
84). Here, we demonstrate that NOXA bound to MCL1 leading to its degradation following
entinostat and pimasertib treatment. This was associated with activation of
mitochondrial/proteasome-mediated apoptosis in SUM190PT and SUM149PT cell lines as
measured through BIM, BAX, BAK, and caspase-3 and -9 cleavages in vitro and in vivo,
whereas single or combination treatments failed to reduce tumorigenic potential and induce
apoptosis in the treatment-resistant HCC1806 cells, which lack entinostat-mediated NOXA
mRNA induction. We suggest that the minimal treatment effects inducing apoptosis on
HCC1806 cells may be attributed to entinostat ability to inhibit cell proliferation by inducing
p21-mediated G1 cell cycle arrest following low doses of entinostat treatment, as reported by
others (85). Therefore, the clinically relevant entinostat doses tested in our study may not be
effective at inducing apoptosis in the HCC1806 cell line. Further investigation is necessary to
fully understand the potential mechanisms of inducing treatment resistance.

We recognize that there are slightly different treatment sensitivity levels observed
between the SUM190PT and SUM149PT cell lines, which may be due to diverse NOXA/MCL1
binding abilities, NOXA mRNA induction levels, or SUM190PT HER2-positivity possibly
affecting NOXA expression via TP53. There is evidence that HER2 signaling negatively
regulates the function of TP53, a known positive regulator of NOXA expression, making it
possible for HER2 to have an indirect inhibitory role on NOXA via TP53 (86). Additionally, we
have previously identified that entinostat can sensitize trastuzumab/lapatinib-resistant HER256

positive cells to treatment by induction of apoptosis via FOXO3-mediated Bim1 expression
(40). Therefore, future studies into the potential role of HER2 positivity in relation to NOXA, as
well as a potential rationale for an entinostat-trastuzumab-pimasertib triple-combination therapy
for instance, needs to be further explored as a possible therapeutic approach in HER2-positive
breast cancer.

Inhibition of pro-apoptotic NOXA through siRNA, as well as vector-induced expression
of anti-apoptotic MCL1, significantly induced resistance of SUM190PT and SUM149PT cells
to entinostat and pimasertib separately, as well as to combination treatment, when compared to
control transfections. Our findings confirmed the important role NOXA plays in sensitivity of
TNBC and IBC cell lines to combination treatment, in that transient transfection of a NOXAexpressing vector reduced MCL1 protein levels, as well as sensitized the cells in combination
with pimasertib. Further experiments should be done to provide more evidence supporting the
direct role of NOXA and MCL1 driving combination treatment sensitivity, such as by
developing NOXA and MCL1 protein inducible expression/suppression models, as well as
constructs with mutated functional domains to determine their individual roles affecting
combination treatment synergy.

IBC and TNBC remain diseases without an effective targeted therapy that can
significantly affect patients’ morbidity and/or survival. Our study provides preclinical evidence
for the translational potential of a combined entinostat and pimasertib therapy for patients with
the most aggressive molecular and clinical diagnoses of breast cancer, TNBC and IBC,
especially for those with tumors expressing high levels of MCL1 and p-ERK, or increased levels
following initial entinostat treatment. Although p-ERK has been reported to be a biomarker of
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poor prognosis in breast cancer (87), a potential challenge for the clinical application of our
therapeutic strategy is that there are no treatment-predictive biomarkers established for the
selection of patients who could benefit from MCL1-inhibition treatment. With the goal of
discovering such a biomarker, a chemical genomic study identified that tumors with low
expression of BCL-xL, an anti-apoptotic BCL2 family member, were associated with sensitivity
of breast and non-small cell lung cancer tumors in vivo to compounds that inhibit MCL1,
representing a potential strategy that may be established in the clinic for the selection of patients
who could benefit from MCL1-inhibition treatments (88). More importantly, the genomic and
proteomic analyses performed in our current study are translatable to the clinical trial setting,
allowing the study of baseline and treatment-induced MCL1 and NOXA expression levels in
patient tumors. As supported by the results of our in vivo studies, the inclusion of MCL1 and
NOXA expression measurement could provide robust predictive biomarkers of treatment
response to entinostat and pimasertib combination therapy.
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CHAPTER 4: IDENTIFICATION OF A COMBINATIONAL THERAPY STRATEGY
OF EICOSAPENTAENOIC ACID AND EPHA2-TARGETING AGAINST TN-IBC

4.1 Introduction
4.1.1 Inflammation in cancer
Inflammation is a biological process designed to fight infections and heal wounds.
Inadvertently, inflammation can support tumor formation, growth and angiogenesis by
supplying bioactive molecules that facilitate progression and metastasis in multiple types of
cancer, including that of the breast (89-91). Large-scale studies of genetic variations of
inflammation across cancer sites has indeed revealed an association with increased risk of
cancer development, suggesting inflammation as an initiator or promoter of cancer (92). There
are two distinct types of inflammation associated to tumor formation: tumor-extrinsic, and
tumor-intrinsic. Tumor-extrinsic inflammation can involve multiple factors, such as obesity,
autoimmune diseases, bacterial/viral infections, tobacco exposure, and alcohol consumption,
which can increase the risk of cancer occurrence and promote its progression (93). Cancerintrinsic inflammation on the other hand, is triggered by the aberrant expression of cancerassociated genes within a cell, contributing to tumor progression by recruiting and activating
inflammatory cells to its microenvironment (93). Both the extrinsic and the intrinsic types of
inflammations can subsequently result in immunosuppression of the surrounding of a malignant
cell providing an ideal microenvironment for the development of a tumor.

4.1.2 Inflammation in TN-IBC
Pathological assessment of triple-negative IBC (TN-IBC) has identified increased
expression of molecular mediators of inflammation, such as COX2 (prostaglandin G/H synthase
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2), and prostaglandin E2 (PGE2), representing potential therapeutic targets (94). Therefore, this
suggests the potential to investigate compounds that can target these inflammatory molecules
for the treatment of TN-IBC.

4.1.3 Anti-inflammatory compounds against TN-IBC
The majority of cells involved in cancer –associated inflammation are genetically stable
and not subject to the emergence of drug resistance, therefore targeting inflammation represents
a viable strategy for cancer therapy. In clinical trials, the consumption of non-steroidal antiinflammatory drugs, such as aspirins, naproxen and ibuprofen, has been associated to a reduced
cancer risk, and long-term reduction in the incidence and mortality for several cancer types
including breast cancer (95). Therefore, those findings suggests the use of anti-inflammatory
compounds and specific inhibitors of inflammatory pathways for the treatment and prevention
of cancer.

Recent findings from our laboratory have demonstrated that inhibition of inflammatory
pathways such as through the use of celecoxib, a COX2 inhibitor, or lovaza which contains
omega-3 fatty acids with anti-inflammatory properties, can inhibit the growth of TN-IBC cells
in vitro and of tumors xenografts in vivo.

4.1.3.1 Eicosapentaenoic acid (EPA)
Eicosapentaenoic acid (EPA), a polyunsaturated omega-3 fatty acid which has been
approved for the treatment of hypertriglyceridemia, is additionally known to inhibit
inflammatory pathways, and has been observed to inhibit tumor initiation, progression, and
growth in vivo by exerting anti-inflammatory effects in cancer cells (96, 97). Evaluation of an
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U.S. Food and Drug Administration (FDA)-approved EPA-purified form, Vascepa, has been
observed to have a safer toxicological profile than other available omega-3 fatty acids, such as
docosahexaenoic acid (DHA), providing an ideal anti-inflammatory compound to be
investigated as a therapeutic agent against TN-IBC (98, 99). Omega-3 fatty acids such as EPA
can also modulate cancer cells motility by incorporating into the plasma membrane in where
they modify lipid rafts increasing membrane compaction, modification of intracellular signaling,
and inhibition of invasiveness of cancer cells (Figure 23) (100-102).

Figure 23. Diagram of EPA activity in cell membrane and intracellular pathways.
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4.1.4 Ephrin family of receptor tyrosine kinases
The Ephrin molecules comprise the largest family of receptor tyrosine kinases in the
mammalian genome, and are expressed at variant levels in most cell types (103). Ephrins are
known to be associated to inflammatory diseases, as well as increasingly recognized as
important players in carcinogenesis (104). Ephrin receptors (EPHs) and their receptor
interacting proteins (Ephrin) ligands, can be classified based on their sequence homology,
receptor-ligand binding preferences, and ephrin membrane anchorage (105). An important
signature of EPHs/ephrins are their bidirectional signaling by which they control multiple
biological functions associated to cellular homeostasis (106). Alteration in EPHs/ephrins
signaling in humans, and particularly EPH receptor ligand-independent functions, have been
associated to aberrant cell functions and oncogenic features (107).

4.1.4.1 Ephrin type-A receptor 2 (EPHA2)
Among EPHs, emerging evidence on the ligand independent functions of the EPH
receptor EPHA2, continue to accumulate in association to cancer progression. EPHA2, a cellsurface receptor tyrosine kinase associated to proto-oncogene tyrosine-protein kinase Src (SRC)
signaling, is aberrantly expressed in multiple cancer types in where it plays an important ligandindependent role in tumor growth and metastasis (108-110). As a cell surface receptor, EPHA2
localization has been implicated in the modulation of gap junctions and cell plasma membrane
fluidity attributing to increased cell motility in tumor invasion (111-113). Therefore, EPHA2 is
an emerging molecule of interest for therapeutic targeting in cancer.
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4.1.5 Gap in Knowledge
Even though the efficacy of anti-inflammatory compounds have been demonstrated to
improve cancer patients outcome, the translation of anti-inflammatories as a monotherapy,
including omega-3 fatty acids, has been largely ineffective in solid tumors (114, 115).
Additionally, the regulation of EPA in cancer cell plasma membrane fluidity status have been
implicated to the modulation of invasive and metastatic potential (116-118). However, there has
not been evidence of increased membrane rigidity as a mechanism of apoptosis induction
following combination therapy against TN-IBC. Therefore, the ability of EPA to kill cancer
cells at concentrations well tolerated in humans, as well as its anti-inflammatory and membrane
fluidity regulatory properties, support development of a novel EPA-based combinational
treatment that enhances its efficacy for the treatment of TN-IBC patients.
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4.2 Results
4.2.1 Eicosapentaenoic acid reduces tumor growth in a TN-IBC xenograft model
Polyunsaturated omega-3 fatty acids (PUFAs), such as EPA, have been observed to
inhibit tumor initiation, progression and growth in vivo by exerting anti-inflammatory effects in
cancer cells (96, 97). In particular, compared to other PUFAs supplements, EPA has additional
health benefits making it the safest option (98). To assess EPA effects inhibiting tumor growth
and prolonging survival in a pre-clinical xenograft model of TN-IBC, SUM149PT, we evaluated
the mice treated with EPA at the dose equivalent to the human FDA-approved (0.8 g/kg), as
well as half-dose (0.4 g/kg) (Figure 24). After treatment with EPA-diets (n = 10 per group)
tumor and blood serum samples were collected when mice reached study endpoint (morbidity,
or tumor burden of 1,500 mm3) for further analysis, including EPA lipid content. We validated
the incorporation of EPA in serum total lipids (Figure 25A), as well as within the tumor
phospholipid fraction (Figure 25B), in a dose-dependent manner. Moreover, we observed a
significant inhibition of tumor growth (Figure 25C), and prolonged survival to endpoint
(Figure 25D), on mice receiving 0.8 g/kg EPA when compared to half dose and control (P <
0.05). These data validates a potential role for EPA inhibiting TN-IBC tumor growth, and
prolonging survival, but also provides evidence for the potential lack of efficacy for EPA as a
monotherapy for cancer. Therefore, there is a need to identify a potential combination strategy
that could enhance the therapeutic efficacy of EPA in treating TN-IBC.

4.2.2 Identification of EPHA2 as a clinically relevant target that can enhance EPA therapy
against TN-IBC
To identify a potential candidate that enhances the sensitivity of TN-IBC cells to EPA,
we performed a functional genomic, synthetic-lethal siRNA screen in SUM149PT cells.
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Figure 24. EPA (Vascepa) formulated diet equivalent to daily human dose. Customized AIN76A mice diets containing the FDA-approved EPA purified form, Vascepa, were validated by
chromatographic fatty acid analysis to contain doses equivalent to the human full (4 g) and half (2 g)
daily doses: 6 and 3 g of Vascepa per kg of mice diet. These diets EPA concentrations are equivalent
to mice EPA daily intakes of 0.8 and 0.4 g/kg, respectively, considering an average daily food intake
of 3.5 g, and average mice weight of 25 g.
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Figure 25. Eicosapentaenoic acid reduced tumor growth in a preclinical model of TN-IBC. EPA
dose dependently inhibited tumor growth, and prolonged mice survival. Following EPA treatments
(0.4 and 0.8 g/kg), the mol percentage of EPA in serum total fatty acids (FA) was analyzed by gas
chromatography/mass spectrometry (A), and the tumor phospholipid fraction (B). (C) Tumor growth
(volume), and (D) survival (endpoint = 1,500 mm3 tumor) were measured for SUM149PT tumorbearing mice treated with EPA. Unpaired T-test: *, P < 0.05; **, P < 0.001; ***, P < 0.0001. Logrank: ‡, P < 0.05 compared to EPA 0.4 g/kg and control.
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Figure 26. Diagram of functional high-throughput siRNA screen identifies candidate genes
sensitizing TN-IBC cells to EPA therapy.

We employed a siRNA library directed against kinase genes for which FDA-approved drugs are
currently available (Figure 26). To identify top candidates, we applied two selection criteria,
namely: 1) absence of toxicity when the target is inhibited without EPA treatment, and 2)
significantly enhancing the efficacy of EPA upon combination treatment. Using these criteria,
we identified a total of 20 genes sensitizing SUM149PT cells to EPA, with EPHA2, DUSP4 and
EDG2 among the top three candidates (Table 3 and Figure 27A). Secondary validation using
the specific inhibition of EPHA2, DUSP4 and EDG2 by multiple individual siRNAs, provided
evidence for the candidates’ potential enhancing the sensitivity of SUM149PT cells to EPA
treatment (Figure 27B). Among top three candidates, we decided to focus on EPHA2, a cell
surface receptor tyrosine kinase, because of the known association of its increased expression
67

with cancer progression (119). These results identify EPHA2 as a lead target for an EPA-based
combination therapy in TN-IBC.

We pursued further studies to determine the clinical significance of EPHA2 expression
among breast cancer patients. To achieve this, we analyzed the relevance of EPHA2 expression
in breast cancer cell lines among published mRNA expression datasets (120), as well as inhouse protein assessment. TNBC cell lines were significantly associated to higher EPHA2
protein (Figure 28A-B), and mRNA (Figure 29), expression when compared to cell lines from
the other breast cancer subtypes HER2 positive, or hormone receptor (HR) positive. We further
investigated EPHA2 expression in association with disease-free survival (DFS) using the
BreastMark web-based mRNA dataset of breast cancer patient samples (50). Consistent with our
findings in breast cancer cell lines, Kaplan-Meier survival curves revealed high EPHA2
expression to be specifically correlated with poor TNBC (basal-like) patient DFS, while not to
HER2- or HR-positive patients (Figure 30). Together, these results strongly suggest the clinical
significance of EPHA2 targeting, with specific clinical implications for the treatment of TNIBC.

4.2.3 EPHA2 therapy in combination with EPHA2 inhibition synergistically kills cells
through induction of apoptosis
To define the role of EPHA2 enhancing an EPA-based combination therapy in TN-IBC,
we utilized functional gene silencing and drug-based inhibition studies. We geneticallyengineered two TN-IBC cell lines, SUM149PT and BCX010, to express a doxycycline (dox)inducible EPHA2-shRNA cassette using the pTRIPZ lentiviral system (Figure 31). We
established two TN-IBC cell lines, SUM149PT and BCX010, transduced with doxycycline
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Table 3. Candidate genes significantly affecting SUM149 TN-IBC cells sensitivity to EPA.
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Figure 27. Top significant targeting candidates enhance TN-IBC cells sensitivity to EPA. EPHA2,
DUSP4 and EDG2 were validated as a top candidates sensitizing TN-IBC cells to EPA therapy. (A)
Viability readout of the top 12 significant gene siRNAs from high-throughput siRNA synthetic-lethal
functional screening sensitizing SUM149PT cells to EPA. TOX and OTP3 were used as positive and
negative transfection controls, respectively. (B) EPHA2, DUSP4 and EDG2 inhibition was validated by
immunoblotting analysis with anti-EPHA2, -DUSP4, and –EDG2 antibodies (top), and viability assays
(bottom), after transfection with EPHA2, DUSP4, and EDG2-siRNAs in combination with EPA
treatment, compared to untreated, parental and scrambled control (siSCR) transfections. Data were
pooled from three independent experiments and presented as mean ± SD. Unpaired T-test: *, P < 0.05;
**, P < 0.0001.

70

Figure 28. Basal EPHA2 protein expression is present in most TN and TN-IBC cell lines. (A)
EPHA2 protein expression levels were determined in multiple human and mouse breast cancer cell lines
by immunoblotting analysis. Breast cancer cell lines are grouped by hormone receptor positive (HR+),
HER-2 positive (HER2+), or triple-receptor negative (TNBC) status. (B) The pixel density ratios of
EPHA2/actin for each cell line was used to generate the graph; β-actin expression was used as a protein
loading control. Unpaired T-test: *, P < 0.0001.
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Figure 29. EPHA2 mRNA expression is predominantly higher in TNBC cell lines. EPHA2 mRNA
expression levels were determined between TNBC and non-TNBC cell lines using a previously
published dataset of breast cancer cell lines. Unpaired T-test: *, P < 0.0001.
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Figure 30. EPHA2 is a clinically significant target that enhances TN-IBC cells sensitivity to
EPA. Kaplan-Meier survival curve for disease-free survival (DFS) of TNBC/basal-like breast cancer
patients using the BreastMark mRNA dataset was used to determine correlation to EPHA2 tumor
mRNA levels. The log-rank test was used to compare survival curves for high versus low EPHA2.
The initial numbers of patients at risk in each group are indicated in the key.
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Figure 31. Diagram of gene-silencing, and drug targeted, inhibition of EPHA2 strategies to be
tested in combination with EPA treatment.
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Figure 32. Gene silencing and targeted EPHA2 inhibition acts synergistically with EPA against
TN-IBC in vitro. EPHA2 inhibition decreased proliferation and enhanced apoptosis induction
following combination treatments with EPA. (A), EPHA2 gene silencing in SUM149PT and BCX010
doxycycline-inducible shRNA cell lines confirmed by immunoblotting analysis of EPHA2 protein
expression. (B), Proliferation (top), and apoptosis (bottom), levels were determined EPHA2
knockdown TN-IBC cell lines using cell proliferation and Annexin V staining, respectively, following
doxycycline (Dox) induction in combination with EPA. (C), Inhibition of EPHA2 activity was
confirmed following EPA and dox-inducible shEPHA2 treatments by immunoblotting analysis. (D)
Effects of dasatinib treatment on EPHA2 and SRC was assessed by immunoblotting. Expression of αtubulin and β-actin were used as a protein loading control. (E), Proliferation (top), and apoptosis
(bottom), levels were similarly assessed in SUM149 and BCX010 cell lines following dasatinib in
combination with EPA. Data were pooled from three independent experiments and presented as mean
± SD. Unpaired T-test: *, P < 0.05; **, P < 0.001; ***, P < 0.0001.
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(dox)-inducible EPHA2-shRNA (Figure 32A). Treating with doxycycline in combination with
EPA, we observed synergistic cell growth inhibition and induction of apoptosis (P < 0.05)
(Figure 32B). Silencing of EPHA2 protein activity following treatments was confirmed by
immunoblotting analysis (Figure 32C). In a second complimentary approach, we assessed the
efficacy of IC50 concentrations of dasatinib (Table 4), a small molecule inhibitor that targets
EPHA2 and SRC, to successfully target EPHA2 and SRC protein activity (Figure 32D). Upon
dasatinib treatment in combination with EPA, we observed a significant inhibition of cell
growth (P < 0.001), as well as induction of apoptosis (P < 0.05), in SUM149PT and BCX010
cell lines when compared to monotherapy and untreated controls (Figure 32E). These data
supports the efficacy of EPHA2-targeting as a partner that enhances the cytotoxicity of EPA
against TN-IBC.

Table 4. IC50 values of breast cancer cell lines following EPA and dasatinib single and combination
treatments.
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4.2.4 Combination treatment of EPA and EPHA2 inhibition modifies the cell membrane
rigidity status and lipid structure of TN-IBC cell lines.
Highly lipophilic EPA is known to incorporate in the plasma membrane of cells in where
it can alter membrane structure and protein localization (101). In order to determine the
incorporation of EPA in TN-IBC cells membrane, we evaluated EPA content on SUM149PT
cell plasma membrane fraction by mass spectrometry following in vitro supplementation with
EPA (Figure 33A). After confirming the incorporation of EPA in cell membranes, we
proceeded to determine if EPA plays a direct role modulating EPHA2 protein expression and
cell surface localization. Using immunoblotting and flow cytometry analysis, we were able to
determine that even though EPA treatment does not significantly affect whole cell EPHA2
expression, it does plays a role inducing the internalization of EPHA2 receptor from the cell
surface (Figure 33B). These results suggest that while EPA may not affect EPHA2 protein
expression, it could be directly affecting EPHA2 signaling by inducing its internalization from
TN-IBC cells surface.

To explore the role of EPA treatment in combination with EPHA2 inhibition in TN-IBC
cells plasma membrane, we evaluated the general polarization status following combination
treatments. After treatments, we identified an increase in cell membrane general rigidity
following combination therapy in SUM149PT and BCX010 cells (P < 0.001 and 0.05,
respectively), when compared to monotherapy and untreated control (Figure 34A-B). These
results indicate that specific inhibition of EPHA2 in combination with EPA treatment
significantly increase cell membrane rigidity.
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Following our findings on the increased cell membrane rigidity status after EPA and
EPHA2-inhibition combination treatments, we proceeded to confirm this phenomenon by
evaluating the lipid profile of a main membrane phospholipid group, the phosphatidylcholine
(PC) family, by mass spectrometry (Figure 35). Following single and combination EPA and
EPHA2-shRNA doxycycline-inducible inhibition in SUM149PT cells, we observed a trend
towards higher abundance of longer carbon structure PC family members in cell membrane
following EPA monotherapy, and even more so when combined with EPHA2-shRNA inhibition
(Figure 36A). This is also evidenced by abundance of each carbon and unsaturation number
subfamilies, which also significantly trend towards higher carbon and unsaturation number
structures (Figure 36B). These data suggest that upon combination of EPA and EPHA2
inhibition, the PC lipid family is slightly modified in the direction of longer-carbon family
members, which is consistent with increased membrane rigidity, or polarization, status.

Because cholesterol is a main regulator of membrane rigidity in cells, we evaluated cell
plasma membrane cholesterol content in association to increased membrane rigidity after EPA
and EPHA2-inhibition combination therapy. After EPA treatment in combination with EPHA2
inhibition, we identified a significant accumulation of cholesterol incorporated in the plasma
membrane of SUM149 and BCX010 cells after combination treatments, when compared to
monotherapies (P < 0.05) and untreated control (P < 0.001) (Figure 37). Collectively, these
results suggest that combination EPA and EPHA-inhibition treatment significantly increase cell
membrane rigidity by increasing cholesterol accumulation in the plasma membrane of TN-IBC
cells.
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Figure 33. EPA in combination incorporates in the plasma membrane, and induces the
internalization of EPHA2. (A), Detection of EPA within TN-IBC cells membrane following
treatment. (B), Total (top), and cell surface (bottom), EPHA2 protein expression after EPA
treatment in TN-IBC cell lines, as determined by immunoblotting and flow cytometry,
respectively. Actin was used as a protein loading control; IgG was used as a negative control for
flow cytometric analysis. *, P < 0.05; **, P < 0.001; *** P < 0.0001
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Figure 34. Combination treatment of EPA and EPHA2-inhibtion increases plasma cell membrane
rigidity on TN-IBC cell lines. Imaging (A) and quantification (B) of cell membrane general
polarization (GP, rigidity) after treatments with EPA in combination with doxycycline inducible EPHA2shRNA (Dox), or dasatinib, in SUM149PT and BCX010 cells. Higher GP values indicate increased cell
membrane compaction/rigidity. Data were pooled from three independent experiments and presented as
mean ± SD. T-test: *, P < 0.05; **, P < 0.001; *** P < 0.0001.
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Figure 35. Phosphatidylcholine plasma membrane lipid profiling of SUM149PT cells after
EPA and EPHA2-targeting treatments. Complete Phosphatidylcholine (PC) lipid species
relative abundance profile quantified by mass spectrometry analysis. PC species are grouped by
smaller (A), and larger (B), carbon structure in the membrane of SUM149PT-shEPHA2 inducible
cells after treatments with EPA (55 µM) in combination with EPHA2-shRNA (Doxycycline, 1
µg/mL). Data were pooled from at three independent experiments and presented as mean ± SD.
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Figure 36. Combination treatment of EPA and EPHA2-inhibtion modifies plasma cell membrane
lipid composition of TN-IBC cell lines. (A), Heat map for the relative abundance profile of
Phosphatidylcholine (PC) phospholipid family members quantified by mass spectrometry analysis after
EPA and EPHA2-shRNA (Dox, 1 µg/mL) in doxycycline inducible SUM149PT cells, sorted from
lower to higher family member carbon and unsaturation (carbon:unsaturation) number. (B), Summary
of PC lipid profile grouped by carbon (top) and unsaturation (bottom) number. Data were pooled from
three independent experiments and presented as mean ± SD.
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Figure 37. Cholesterol accumulates in plasma membrane fraction following EPA and EPHA2inhibition treatment. Quantification of cholesterol concentration in the membrane fraction of
SUM149PT and BCX010 cells after treatments with EPA in combination with EPHA2-shRNA
(Dox), or dasatinib. Data were pooled from three independent experiments and presented as mean ±
SD. Unpaired T-test: *, P < 0.05; **, P < 0.001; *** P < 0.0001; ‡, P < 0.05 compared to EPA; §, P <
0.0001, compared to dasatinib or doxycycline.
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4.2.5 The cholesterol exporter protein, ABCA1, is a critical mediator of apoptosis in TNIBC cells response to EPA and EPHA2-inhibition therapy.
Our findings on the increased membrane rigidity by the accumulation of cholesterol in
the plasma membrane prompted us to investigate a role of cholesterol directly regulating TNIBC cell membrane fluidity and treatment sensitivity. We first assessed the effect of cholesterol
in cell membrane rigidity following EPA-based treatments in TN-IBC cells. Following
treatments in addition to cholesterol supplementation, or starvation of cholesterol using methylβ-cyclodextrin (MβCD) (Figure 38 and Figure 39), we observed enhancement (P < 0.05) and
reversal (P < 0.0001), respectively, of cell membrane rigidity compared to combination EPA
and EPHA2 inhibition treatments (Figure 40A). We further determined the role of cholesterol
modulation and cell membrane fluidity affecting TN-IBC cells apoptosis. We identified a direct
correlation between increased membrane rigidity following combination treatment in addition to
cholesterol supplementation and apoptosis induction, when compared to combination treatments
alone, and in combination to rosuvastatin, a cholesterol biosynthesis inhibitor, significantly
reversing cell death induction (Figure 40B). These data suggests that cholesterol may be
responsible for enhancing membrane rigidity and apoptosis induction, potentially suggesting
that cholesterol regulation pathways may be subsequently leading to induction of apoptosis in
TN-IBC.

Figure 38. Diagram for cholesterol modulation techniques used to modify cell membrane fluidity.
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Figure 39. Modulation of cholesterol concentration in the membrane fraction of TN-IBC cells.
Cholesterol concentration in the membrane fraction of SUM149PT and BCX010 cells was
determined using Amplex Red Cholesterol assay after cholesterol removal using Methyl-βcyclodextrin (MβCD: 4 mM), or supplementation (Cholesterol: 1 mM). Data were pooled from five
independent experiments, and represented as mean ± SD. Unpaired T-test: *, P < 0.001.
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Figure 40. Accumulation of intracellular cholesterol plays a role in the induction of apoptosis
following combination EPA and EPHA2-targeting therapy in TN-IBC cells. ABCA1 plays an
important role in the regulation of membrane rigidity by accumulation of intracellular cholesterol in TNIBC cells after combination EPA and EPHA2-inhibition treatment. Quantification of cell membrane
general polarization (rigidity) (A), or fold-induction of apoptosis relative to untreated control (B), after
cellular cholesterol removal (Methyl-β-cyclodextrin, MβCD; or rosuvastatin), or supplementation
(Cholesterol), in TN-IBC cells treated with EPA in combination with Doxycycline-inducible EPHA2shRNA (Dox), or dasatinib. Higher GP values indicate increased cell membrane compaction/rigidity.
Data were pooled from at least three independent experiments and presented as mean of fold-change
compared to untreated control ± SD. Unpaired T-test: *, P < 0.05; **, P < 0.001; *** P < 0.0001; #, P <
0.05 compared to untreated control.

86

Cholesterol homeostasis is a key determinant of cell viability (121, 122). To evaluate
potential cholesterol modulating mechanisms associated to combination treatment, we
determined the expression of main cholesterol exporting (ATP-binding cassette sub-family A
member 1, ABCA1), importing (low-density lipoprotein receptor, LDLR), and biosynthesis
inducer (sterol regulatory element-binding protein2, SREBP-2; and 3-hydroxy-3methylglutaryl-coenzyme A reductase, HMGCR) proteins (Figure 41). Following combination
treatments, we identified significant inhibition of ABCA1 and SREBP-2 when compared to
single treatment and untreated controls (Figure 42). The inhibition of ABCA1 would suggest
that cholesterol may accumulate within cells preventing the molecular activation of the SREBP2 matured form, and leading to an increase in cell membrane rigidity, and subsequently cell
death. To determine whether ABCA1 is a critical component of cell membrane rigidity, we

Figure 41. Diagram of main regulators of cellular cholesterol homeostasis.
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performed gain/loss-of-expression studies to assess the response of SUM149PT and BCX010
cells to combination treatment (Figure 43A-B). Over-expression of ABCA1 reversed cell
membrane rigidity following EPA therapy, as well as cell death induction, when compared to
controls (Figure 43C-D). In a reverse-complimentary approach, ABCA1-silenced TN-IBC cells
displayed increased cell membrane rigidity, and cell death, when compared to controls (Figure
43C-D). These results provide direct evidence for the requirement of ABCA1 inhibition for
effective EPA combination therapy synergism in TN-IBC by increased membrane rigidity and
apoptosis induction. Lastly, we evaluated whether we could further confirm the relevance of
cholesterol accumulation as a crucial factor that promotes TN-IBC cells cytotoxicity following
ABCA1 mRNA silencing. After inhibition of cholesterol biosynthesis by rosuvastatin, we
observed a significant inhibition of apoptosis induction in ABCA1-silenced SUM149PT and
BCX010 cells compared to single rosuvastatin or ABCA1-siRNA conditions (Figure 44).
Altogether, this data confirms a role for ABCA1 inhibition and cholesterol accumulation as
important factors that regulate treatment synergism of combination EPA and EPHA2 inhibition
against TN-IBC.
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Figure 42. ABCA1 and SREBP-2 are inhibited following combination therapy of EPA and
EPHA2-inhibtion in TN-IBC cells. Immunoblotting assay of main cholesterol homeostasis regulating
proteins: ABCA1, matured SREBP-2, HMG CoA Reductase (HMGCR), and LDL-Receptor (LDLR)
matured (M) and precursor (P) forms after EPA in combination with EPHA2-shRNA (Dox), or
dasatinib. Pixel density of proteins were quantified for each condition, and the ratios of protein/β-actin
or treatment/control are shown next to the blots; β-actin expression was used as a protein loading
control.
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Figure 43. ABCA1 modulation is responsible for the induction of apoptosis following
combination EPA and EPHA2-targeting therapy in TN-IBC cells. SUM149PT and BCX010 cells
were transfected with either an ABCA1-expressing vector or empty control vector (A), or pooled
ABCA1 (siABCA1) or Scrambled (SCR) siRNA (B). Pixel density of proteins were quantified for
each condition, and the ratios of protein/β-actin or treatment/control are shown next to the blots; βactin expression was used as a protein loading control. ABCA1 expression vector or siRNA
transfection role in membrane general polarization (rigidity) (C), and fold-induction of apoptosis
relative to untreated control (D), in TN-IBC cells after combination of EPA with EPHA2-shRNA
(Dox), or dasatinib. Data were pooled from at least three independent experiments and presented as
mean of fold-change compared to untreated control ± SD. Unpaired T-test: *, P < 0.05; **, P < 0.001;
*** P < 0.0001; #, P < 0.05 compared to untreated control.
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Figure 44. Cholesterol accumulation induces apoptosis following ABCA1-siRNA inhibition. TNIBC cells were transfected with ABCA1 siRNA, alone or in combination with rosuvastatin, for analysis
of apoptosis using annexin V-green. Data were pooled from at least three independent experiments and
presented as mean of fold-change compared to untreated control ± SD. Unpaired T-test: *, P < 0.05.
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4.2.6 Inhibition of EPHA2 enhances the therapeutic action of EPA in TN-IBC xenograft
models
Our in vitro data infers that EPA therapy combined with EPHA2 inhibition would be an
effective therapy. We proceeded to determine whether inhibition of EPHA2, both by gene
silencing and targeting drug dasatinib, could enhance EPA efficacy inhibiting tumor growth in
preclinical xenograft models of TN-IBC. Mice bearing established (Figure 45A-B) SUM149PTshEPHA2 or BCX010-shEPHA doxycycline-inducible tumor xenografts received ad libitum
administration of EPA containing diets alone or in combination with doxycycline water. When
compared to mice treated with control diets or single treatments, combination treated mice
displayed a significant reduction in TN-IBC tumor growth (P < 0.001) (Figure 46A), and
prolonged survival (P < 0.001) (Figure 46B). Immunostaining for markers of proliferation and
apoptosis in tumors after combination treatment confirmed a significant reduction of Ki67, and
an increase in cleaved caspase-3 (P < 0.05) (Figure 46C-D). As expected, our combination
therapy inhibited EPHA2 leading to modified expression of cholesterol regulator ABCA1
compared to single and control groups (P < 0.05) (Figure 47A-B). These findings confirm the
efficacy of specific EPHA2-inhibition sensitizing TN-IBC tumors to EPA treatment via
inhibition of ABCA1 as a potential therapeutic approach for further preclinical development.

Supported by our findings on the efficacy of EPHA2 gene silencing enhancing EPA
therapy in vivo, we proceeded to assess the ability of dasatinib sensitizing TN-IBC tumors to
EPA. Similar to our previous animal study, mice bearing TN-IBC tumor xenografts received
EPA alone or in combination with dasatinib. Combination treatment displayed inhibition of
tumor growth (P < 0.05) (Figure 48A), as well as prolonged survival (P < 0.001) (Figure 48B),
when compared to single treatment and untreated mice groups. Immunostaining of tumor tissues
92

following treatments confirmed a reduction in Ki67 proliferation marker, and increase in
cleaved caspase-3 apoptosis marker following combination treatments in comparison to single
and untreated controls (P < 0.05) (Figure 49A-B). Confirming our in vitro molecular studies, we
identified a reduction of tumor EPHA2 protein expression following dasatinib treatment.
Moreover, we identified inhibition of ABCA1 protein expression after combination treatment (P
< 0.05) (Figure 49C-D). Together, these results provide evidence supporting the clinical
development of an EPHA2-targeting therapy in combination with EPA against TN-IBC through
a mechanism involving increased cell membrane rigidity mediated by ABCA1 inhibition.
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Figure 45. Establishment of inducible shRNA-RPHA2 TN-IBC cell lines in xenograft models.
Doxycycline-inducible shRNA-EPHA2-GFP SUM149PT and BCX010 cell lines induction efficacy
was assessed in tumor xenografts in mice. (A), Tumor volume measurements of non-coding shRNA
SUM149PT and BCX010 tumor xenografts following treatment with doxycycline (Dox) in water (2
mg/mL; ad libitum). (B), Flow cytometry analysis using anti-EPHA2 APC-labeled antibody in Red
Fluorescent Protein (RFP) positive cells derived from Dox treated mice bearing non-coding-, and
EPHA-targeting, shRNA-RFP inducible SUM149PT tumor xenografts. EPHA2 expression was
quantified from five mice per treatment group. Data is presented as mean ± maximum/minimum
values. T-test: *, P < 0.001.
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Figure 46. Gene silencing inhibition of EPHA2 acts synergistically with EPA against TN-IBC
tumor xenografts. ShRNA-inducible EPHA2 inhibition enhances EPA efficacy in TN-IBC cell lines.
Tumor volume measurements (A), and Kaplan-Meier survival curves to endpoint (tumor volume =
1,500 mm3) (B) for shEPHA2 inducible TN-IBC tumor xenograft-bearing mice following treatment
with control diet, EPA diet (0.8 g/kg), and/or doxycycline (Dox) in water (2 mg/mL).
Paraformaldehyde-fixed paraffin sections were quantified for proliferation (Ki67) (C), and apoptosis
(Cleaved Caspase-3) (D), protein expression markers by immunohistochemistry (IHC) staining of
three representative tumor samples from each treatment group of mice bearing tumor xenografts
treated with control or treatments as indicated above. Images were converted using ImageJ software to
accomplish the quantifications of Ki-67 and Cleaved Caspase-3 antibody staining. Data is represented
as mean ± SD. T-test or Log-Rank: *, P < 0.05; ‡, P < 0.001 combination treatment survival
proportion compared to single treatment and untreated control groups.
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Figure 47. Inhibition of EPHA2 following gene silencing and EPA treatment inhibits ABCA1 in
TN-IBC tumor xenografts. IHC staining and expression quantifications from shEPHA2 inducible
TN-IBC tumor xenograft-bearing mice following treatment with control diet, EPA diet (0.8 g/kg),
and/or doxycycline (Dox) in water (2 mg/mL), using anti-phospho-EPHA2 (p-EPHA2) (A), and antiABCA1 (B) antibodies. Representative images of three IHC staining experiments per treatment group
are illustrated. Magnification, 20x. Images were converted using ImageJ software to accomplish the
quantifications of p-EPHA2, and ABCA1 antibody staining. Data is represented as mean ± SD. T-test:
*, P < 0.05.
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Figure 48. Dasatinib EPHA2-targeted inhibition enhances EPA therapy against TN-IBC tumor
xenografts. EPHA2 inhibition by dasatinib is synergistic in combination with EPA therapy inhibiting
tumor growth, and prolonging mice survival. Tumor volume measurements (A), and Kaplan-Meier
survival curves to endpoint (tumor volume = 1,500 mm3) (B) for SUM149PT and BCX010 tumor
xenograft-bearing mice following treatment with control diet, EPA diet (0.8 g/kg; ad libitum), and/or
dasatinib (2.5 mg/mL; IP injection). Data is represented as mean ± SD. T-test or Log-Rank: *, P <
0.05; **, P < 0.001; *** P < 0.0001; ‡, P < 0.0001 combination treatment survival proportion
compared to single treatment and untreated control groups.
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Figure 49. Inhibition of EPHA2 following dasatinib and EPA treatment inhibits ABCA1 and
promotes apoptosis in TN-IBC tumor xenografts. Paraformaldehyde-fixed paraffin sections for
SUM149PT and BCX010 tumor xenograft-bearing mice following treatment with control diet, EPA diet
(0.8 g/kg; ad libitum), and/or dasatinib (2.5 mg/mL; IP injection), were quantified for proliferation (Ki67)
(A), and apoptosis (Cleaved Caspase-3) (B) protein markers, as well as for mechanistic proteins: pEPHA2 (C), and ABCA1 (D), by immunohistochemistry (IHC) staining of three representative tumor
samples from each treatment group. Images were converted using ImageJ software to accomplish the
quantifications of Ki-67, Cleaved Caspase-3, p-EPHA2, and ABCA1 antibodies staining. Data is
represented as mean ± SD. T-test or Log-Rank: *, P < 0.05; **, P < 0.001.
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4.3 Discussion
The need to identify new biological therapeutic targets for TN-IBC is undisputed.
Through this study, we have successfully unveiled a novel and clinically significant therapeutic
approach against TN-IBC. Our screen for candidate genes that have synergistic antitumor
activity with EPA in TN-IBC identified EPHA2 as a target that, when ablated, sensitized TNIBC cells to EPA therapy. Suppression of EPHA2 through various approaches enhanced the
antitumor effect of EPA, reducing TN-IBC cell growth and proliferation and promoting
apoptosis. Similarly, combinations of EPA with EPHA2-inhibiting therapy reduced tumor
growth in two in vivo xenograft models of TN-IBC.

EPHA2, a cell-surface receptor tyrosine kinase associated with proto-oncogene tyrosineprotein kinase Src (SRC) signaling, is aberrantly expressed in multiple cancer types, playing an
important ligand-independent role in tumor growth and metastasis (108-110). The localization
of cell surface receptor EPHA2 has been implicated in the modulation of gap junctions and cell
plasma membrane fluidity, contributing to tumor invasion via increased cell motility (111-113).
Modulating cancer cell motility is also one of the functions of omega-3 fatty acids such as EPA,
which incorporate into the plasma membrane, where they modify lipid rafts, increase membrane
compaction, modify intracellular signaling, and inhibit invasive features (100-102). Regulation
of cancer cell plasma membrane fluidity has been implicated in the modulation of invasive and
metastatic potential (116-118). Until now, however, there has been no evidence of increased
membrane rigidity as a mechanism of apoptosis induction following combination therapy
against TN-IBC. Furthermore, the inhibition of the cholesterol-exporting channel protein
ABCA1, followed by accumulation of intracellular cholesterol, and increased membrane rigidity
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preceding TN-IBC cell death in response to the EPA and EPHA2-inhibiting combinations is a
previously unknown mode of action.

Our study has identified EPHA2 as a significant synergistic partner whose loss enhances
EPA therapy, synergistically reducing tumorigenic potential by inducing apoptosis in preclinical
models of TN-IBC. Further, in a retrospective analysis of breast cancer patients, we identified a
significant and specific association between high-EPHA2 expression in tumors and shorter DFS
outcomes in patients with TNBC/basal-like subtype, highlighting the clinical relevance of
targeting EPHA2. Using proteomic and cellular biology assays, we demonstrated that the
combination of EPHA2-inhibition and EPA was significantly associated with a previously
unknown activity that precedes and induces TN-IBC cell death through inhibition of the
cholesterol-exporting channel protein ABCA1 and subsequent increase of membrane cholesterol
levels and membrane rigidity.

Other studies have demonstrated independent roles for EPA and EPHA2 in the
modification of cell membrane fluidity (101, 111). Here, we have identified a direct connection
whereby EPA induces the internalization of EPHA2 from the cell surface and, in concert with
targeted inhibition of EPHA2, enhances cell membrane rigidity. Phospholipid profiling of
cellular membranes provided evidence that membrane rigidity correlated with a significant
increase in expression of longer phosphatidylcholine species (e.g. those with more carbons in
the acyl chains) (data not shown). Cholesterol concentrations also were increased in cell
membranes following combination treatments. Increased cholesterol concentration has been
associated with greater cell membrane rigidity (123, 124). Major regulators of cholesterol
homeostasis in cells include the cholesterol exporter ABCA1, the cholesterol importer LDLR,
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and the cholesterol biosynthesis regulators SREBP2 and HMGCR (125-128). High cholesterol
levels prevent SREBP2 activation, inhibiting the subsequent induction of HMGCR and
maturation of LDLR (Figure 50A) (129, 130). Studies in human macrophages have observed
that incorporation of EPA into the plasma membrane impairs ABCA1-dependent cholesterol
efflux (131, 132), but our study is the first to report this phenomenon in cancer xenograft
models. Here, we demonstrated that suppression of ABCA1 activity by the combination of EPA
and EPHA2-inhibition induced the accumulation of cellular cholesterol contributing to
increased membrane rigidity, inhibition of SREBP2, disruption of cellular lipid homeostasis,
and apoptosis (Figure 50B).

EPA has been widely tested for its benefits as a dietary supplement or as neoadjuvant
therapy in cancer because of its anti-inflammatory qualities and safe toxicity profile (133-136).
This is the first report of its use in a synergistic therapeutic strategy in cancer, providing a safe
and non-toxic approach for treating the highly aggressive breast cancer TN-IBC. These results
provide a rationale for administering EPA in combination with FDA-approved EPHA2-targeting
drugs such as dasatinib, as well as in combination with other specific targeted agents currently
been tested in pre-clinical studies and in humans (e.g., NCT01591356) (137, 138), facilitating
its clinical translation.

TN and IBC remain diseases without effective therapeutic strategies that can
significantly improve patients’ outcomes or survival. Our study is important as we report for the
first time preclinical evidence of combined EPA and EPHA2-targeted therapy effectiveness
against TN-IBC through a mechanism involving the induction of apoptosis by ABCA1
inhibition and subsequent regulation of cell membrane rigidity. Other studies have evaluated the
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potential of ABCA1 inhibition and increased membrane rigidity in association to decreased
metastatic potential, and enhanced efficacy of multiple anti-metastatic drugs (124). This would
suggest that besides induction of apoptosis following ABCA1 inhibition, our combination
therapy strategy could additionally have significant implications preventing metastasis of TNIBC.

Figure 50. Summary of mechanistic action of EPA in combination with EPHA2-targeting via ABCA1
inhibition in TN-IBC cells. Proposed mechanism of action for increased cholesterol concentration and
membrane rigidity mediated by ABCA1 inhibition following combination therapy. (A), Cellular cholesterol
homeostasis is normally maintained by the balancing effects of the cholesterol efflux channel protein
ABCA1, and cholesterol biosynthesis inducer SREBP-2. Their activity promote the maintained fluidity of
the plasma cell membrane and cellular survival. (B), Following combination treatment of EPA and
inhibition of EPHA2 from cells membrane, the plasma membrane structure is altered inhibiting the
cholesterol exporting functions of ABCA1, this resulting in the accumulation of intracellular cholesterol
and subsequent increase in plasma membrane rigidity status. This aberrant accumulation of
intracellular/membrane cholesterol prevents the activity of cholesterol biosynthesis inducer proteins (e.g.
SREPB-2), and disrupts cellular cholesterol homeostasis resulting in apoptosis.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS

5.1 Major findings
Through these projects, I have demonstrated the efficacy of combined HDAC inhibitor
entinostat and MEK inhibitor pimasertib treatments blocking the progression of preclinical
models of TNBC and IBC (Figure 51A). The effectiveness of this therapy has been
significantly associated with the induction of tumor apoptosis regulated by NOXA-mediated
MCL1 degradation. Also, I established the rationale for a novel EPA and EPHA2-targeting
based combination therapy that displays efficacy in EPHA2 positive TN-IBC (Figure 51B). The

Figure 51. Diagram of major mechanisms of synergy involved in our newly discovered
combinational therapies against TNBC and IBC: (A) entinostat and pimasertib, and (B) EPA
with EPHA2-inhibition.
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mechanism of action for EPA/EPHA2-inhibition based therapy relied on the induction of
changes in the membrane of TN-IBC cells as a prelude to induction of cell death.

5.2 Significance
TNBC and IBC are the two most aggressive breast cancers, which still lack effective
targeted therapy options that significantly inhibit tumor burden, or improve patient outcome.
Therefore, the studies presented in this dissertation provide compelling evidence for the efficacy
of novel combination therapies consisting of HDAC and MEK inhibitors, or EPA and EPHA2
inhibition, promoting TNBC and IBC cell death in translational xenograft models. The evidence
developed in these projects additionally provide a strong rationale for the clinical testing of two
novel therapeutic strategies against TNBC and IBC, as well as a basis for the development of
predictive biomarkers for patient stratification and therapeutic response.

Besides breast cancer (139), overexpression of MCL1 has been associated with survival
pathways, resistance, and poor prognosis in multiple cancers, such as melanoma (71), small-cell
lung cancer (140), colorectal cancer (141), oral cancers (142), endometrial cancer (143), as well
as multiple hematological malignancies (72, 144). Therefore, combination treatment of HDAC
and MEK inhibitors may be effective in other cancers, increasing the significance of this study.
However, further validation in clinically relevant models for each disease is needed. Others have
reported data supporting the potential for the combination treatment of MCL1 inhibitors and
inducers of NOXA, providing further evidence of the likely applicability of our combination
treatment (145, 146). Furthermore, we observed sensitivity of IBC and TNBC cells to entinostat
and pimasertib treatment within clinically relevant concentrations, providing a preclinical
rationale for translation into a clinically appropriate dose.
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Overexpression of EPHA2 has been associated with poor prognosis in multiple cancers,
such as colorectal, lung, ovarian, endometrial, and pancreatic, among others (147-152).
Moreover, ABCA1 overexpression was identified to be associated with poor prognosis in breast,
ovarian, and hepatocellular carcinomas (124, 153-155). Therefore, our combination treatment
may be effective in other cancers, thus broadening the importance of this study.

5.3 Future directions
To evaluate the clinical efficacy of the combinational treatment strategies proposed here,
as well as to determine the validity of proposed biomarkers for treatment response and patient
selection, we will translate our results into the development of clinical trials for therapeutic
testing in humans following the reporting recommendations for tumor marker prognostic studies
(REMARK) guidelines (156). The REMARK guidelines provide a standardized method for
study design, development of hypotheses, patient and specimen characteristics, assay methods,
and statistical analysis methods in addition to suggestions for data presentation and discussions.
Complying with these guidelines, we have proposed a Phase 1b clinical trial protocol for the
testing in humans of the HDAC inhibitor entinostat, and a MEK pathway inhibitor selumetinib,
in metastatic breast cancer patients with tumors expressing high MCL1, and low NOXA protein
levels. Detailed information on study design, as well as on specimen characteristic and assay
methods for tumor biomarker studies, are illustrated in detail in Figure 52. This study, expected
to start in late 2017 to early 2018, will be supported by the Cancer Therapy Evaluation Program
(CTEP) of the National Cancer Institute at the National Institutes of Health, and conducted at
The University of Texas MD Anderson Cancer Center in Houston, Texas, by Dr. Naoto T. Ueno
and Dr. Bora Lim from the Department of Breast Medical Oncology and the Morgan Welsh
Inflammatory Breast Cancer Research Program and Clinic.
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Figure 52. Schema of clinical trial for entinostat in combination with selumetinib including
details of biological sample collection for biomarker analysis.

Remaining unclear are the specific reasons why select IBC and TNBC cell lines have
increased NOXA mRNA expression, and NOXA promoter acetylation, in response to entinostat.
Here we noted a tendency for TP53- and BRCA1-mutant cell lines to be unresponsive to
treatment. BRCA1 is a co-activator of TP53 which subsequently induces apoptosis via NOXA,
suggesting a possible escape mechanism when BRCA1 and TP53 are mutated (65). Additionally,
we cannot rule out as possible contributing factors the potential differences in the intracellular
metabolism of entinostat across cell lines, as well as other possible mechanisms by which
entinostat could be modulating NOXA gene expression. Future investigation into the role of
TP53 and BRCA1 mutation status and entinostat intracellular metabolism in association with
NOXA expression and treatment response would be crucial, potentially enabling additional
criteria for patient selection.
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We will also initiate a Phase 1b study to evaluate the clinical efficacy of combination
EPA and EPHA2-targeting therapy in human cancers. Through this second clinical trial,
combination therapy will be tested in breast cancer patients with metastatic disease that have an
elevated tumor expression of EPHA2, and ABCA1, proteins. We will submit this clinical trial
protocol for support by the CTEP in early 2018, to be carried out at The University of Texas
MD Anderson Cancer Center and Morgan Welsh Inflammatory Breast Cancer Research
Program and Clinic in Houston, Texas, by Dr. Naoto T. Ueno and Dr. Bedrich Eckhardt.

Because cell sensitivity to EPA in combination with EPHA2-inhibition seems to be
dependent on cell membrane accumulation of cholesterol, a potential challenge for the clinical
application of our therapeutic strategy is the high percentage (49%) of adults in the U.S.
population currently receiving therapy with cholesterol biosynthesis inhibitors (i.e., statins),
which could reduce the efficacy of EPA and EPHA2-targeting therapy (157-159). However,
statins have been reported to have both tumorigenic and anti-tumorigenic roles, probably due to
their pleiotropic effects. Therefore, the efficacy of the EPA and EPHA2-inhibiting combinations
in patients receiving a statin should be evaluated, together with ABCA1 and EPHA2 protein
expression measurements; such investigations have the potential to provide robust predictive
biomarkers of treatment response to EPA and EPHA2-targeted combination therapy.

The results from these clinical trials would further support the initiation of a Phase II and
III trials for testing the efficacy of these combination treatment strategies in patients with TNBC
and IBC, but also potentially on patients with cancer types that overexpress MCL1, or EPHA2
and ABCA1, respectively (Figure 53). Additionally, the clinically relevant doses tested in our
preclinical models would potentially allow for a significantly decreased toxicity to patients,
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compared to that of cytotoxic chemotherapy and other non-targeting approaches with higher
toxicities.

Figure 53. Summarized overview of clinical trials and biomarker development for proposed
combination therapy strategies in patients with invasive breast cancers.

108

BIBLIOGRAPHY
1.

R. L. Siegel, K. D. Miller, A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin 67, 7-30
(2017).

2.

R. R. Bastien, A. Rodriguez-Lescure, M. T. Ebbert, A. Prat, B. Munarriz, L. Rowe, P.
Miller, M. Ruiz-Borrego, D. Anderson, B. Lyons, I. Alvarez, T. Dowell, D. Wall, M. A.
Segui, L. Barley, K. M. Boucher, E. Alba, L. Pappas, C. A. Davis, I. Aranda, C. Fauron,
I. J. Stijleman, J. Palacios, A. Anton, E. Carrasco, R. Caballero, M. J. Ellis, T. O.
Nielsen, C. M. Perou, M. Astill, P. S. Bernard, M. Martin, PAM50 breast cancer
subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC
Med Genomics 5, 44 (2012).

3.

T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B.
Eisen, M. van de Rijn, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D.
Botstein, P. E. Lonning, A. L. Borresen-Dale, Gene expression patterns of breast
carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci
U S A 98, 10869-10874 (2001).

4.

X. Dai, T. Li, Z. Bai, Y. Yang, X. Liu, J. Zhan, B. Shi, Breast cancer intrinsic subtype
classification, clinical use and future trends. Am J Cancer Res 5, 2929-2943 (2015).

5.

C. M. Perou, T. Sorlie, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R.
Pollack, D. T. Ross, H. Johnsen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C.
Williams, S. X. Zhu, P. E. Lonning, A. L. Borresen-Dale, P. O. Brown, D. Botstein,
Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).

6.

T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H.
Johnsen, R. Pesich, S. Geisler, J. Demeter, C. M. Perou, P. E. Lonning, P. O. Brown, A.
L. Borresen-Dale, D. Botstein, Repeated observation of breast tumor subtypes in
109

independent gene expression data sets. Proc Natl Acad Sci U S A 100, 8418-8423
(2003).
7.

M. C. Cheang, S. K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies,
P. S. Bernard, J. S. Parker, C. M. Perou, M. J. Ellis, T. O. Nielsen, Ki67 index, HER2
status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101,
736-750 (2009).

8.

C. S. Vallejos, H. L. Gomez, W. R. Cruz, J. A. Pinto, R. R. Dyer, R. Velarde, J. F.
Suazo, S. P. Neciosup, M. Leon, M. A. de la Cruz, C. E. Vigil, Breast cancer
classification according to immunohistochemistry markers: subtypes and association
with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 10,
294-300 (2010).

9.

C. Sotiriou, S. Y. Neo, L. M. McShane, E. L. Korn, P. M. Long, A. Jazaeri, P. Martiat,
S. B. Fox, A. L. Harris, E. T. Liu, Breast cancer classification and prognosis based on
gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100,
10393-10398 (2003).

10.

J. D. Brenton, L. A. Carey, A. A. Ahmed, C. Caldas, Molecular classification and
molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23,
7350-7360 (2005).

11.

J. S. Parker, M. Mullins, M. C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C.
Fauron, X. He, Z. Hu, J. F. Quackenbush, I. J. Stijleman, J. Palazzo, J. S. Marron, A. B.
Nobel, E. Mardis, T. O. Nielsen, M. J. Ellis, C. M. Perou, P. S. Bernard, Supervised risk
predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27, 1160-1167
(2009).

110

12.

S. Y. Bae, S. Kim, J. H. Lee, H. C. Lee, S. K. Lee, W. H. Kil, S. W. Kim, J. E. Lee, S. J.
Nam, Poor prognosis of single hormone receptor- positive breast cancer: similar
outcome as triple-negative breast cancer. BMC Cancer 15, 138 (2015).

13.

C. Criscitiello, H. A. Azim, Jr., P. C. Schouten, S. C. Linn, C. Sotiriou, Understanding
the biology of triple-negative breast cancer. Ann Oncol 23 Suppl 6, vi13-18 (2012).

14.

C. Fan, D. S. Oh, L. Wessels, B. Weigelt, D. S. Nuyten, A. B. Nobel, L. J. van't Veer, C.
M. Perou, Concordance among gene-expression-based predictors for breast cancer. N
Engl J Med 355, 560-569 (2006).

15.

L. A. Carey, C. M. Perou, C. A. Livasy, L. G. Dressler, D. Cowan, K. Conway, G.
Karaca, M. A. Troester, C. K. Tse, S. Edmiston, S. L. Deming, J. Geradts, M. C.
Cheang, T. O. Nielsen, P. G. Moorman, H. S. Earp, R. C. Millikan, Race, breast cancer
subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502
(2006).

16.

B. D. Lehmann, J. A. Bauer, X. Chen, M. E. Sanders, A. B. Chakravarthy, Y. Shyr, J. A.
Pietenpol, Identification of human triple-negative breast cancer subtypes and preclinical
models for selection of targeted therapies. J Clin Invest 121, 2750-2767 (2011).

17.

S. Dawood, N. T. Ueno, V. Valero, W. A. Woodward, T. A. Buchholz, G. N.
Hortobagyi, A. M. Gonzalez-Angulo, M. Cristofanilli, Differences in survival among
women with stage III inflammatory and noninflammatory locally advanced breast cancer
appear early: a large population-based study. Cancer 117, 1819-1826 (2011).

18.

S. Chang, S. L. Parker, T. Pham, A. U. Buzdar, S. D. Hursting, Inflammatory breast
carcinoma incidence and survival: the surveillance, epidemiology, and end results
program of the National Cancer Institute, 1975-1992. Cancer 82, 2366-2372 (1998).

111

19.

W. F. Anderson, C. Schairer, B. E. Chen, K. W. Hance, P. H. Levine, Epidemiology of
inflammatory breast cancer (IBC). Breast Dis 22, 9-23 (2005).

20.

J. Li, A. M. Gonzalez-Angulo, P. K. Allen, T. K. Yu, W. A. Woodward, N. T. Ueno, A.
Lucci, S. Krishnamurthy, Y. Gong, M. L. Bondy, W. Yang, J. S. Willey, M.
Cristofanilli, V. Valero, T. A. Buchholz, Triple-negative subtype predicts poor overall
survival and high locoregional relapse in inflammatory breast cancer. Oncologist 16,
1675-1683 (2011).

21.

N. Chaher, H. Arias-Pulido, N. Terki, C. Qualls, K. Bouzid, C. Verschraegen, A. M.
Wallace, M. Royce, Molecular and epidemiological characteristics of inflammatory
breast cancer in Algerian patients. Breast Cancer Res Treat 131, 437-444 (2012).

22.

J. A. Zell, W. Y. Tsang, T. H. Taylor, R. S. Mehta, H. Anton-Culver, Prognostic impact
of human epidermal growth factor-like receptor 2 and hormone receptor status in
inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the
California Cancer Registry. Breast Cancer Res 11, R9 (2009).

23.

H. Matsumoto, S. L. Koo, R. Dent, P. H. Tan, J. Iqbal, Role of inflammatory infiltrates
in triple negative breast cancer. J Clin Pathol 68, 506-510 (2015).

24.

L. T. Steward, F. Gao, M. A. Taylor, J. A. Margenthaler, Impact of radiation therapy on
survival in patients with triple-negative breast cancer. Oncol Lett 7, 548-552 (2014).

25.

F. M. Robertson, M. Bondy, W. Yang, H. Yamauchi, S. Wiggins, S. Kamrudin, S.
Krishnamurthy, H. Le-Petross, L. Bidaut, A. N. Player, S. H. Barsky, W. A. Woodward,
T. Buchholz, A. Lucci, N. T. Ueno, M. Cristofanilli, Inflammatory breast cancer: the
disease, the biology, the treatment. CA Cancer J Clin 60, 351-375 (2010).

26.

I. A. Jaiyesimi, A. U. Buzdar, G. Hortobagyi, Inflammatory breast cancer: a review. J
Clin Oncol 10, 1014-1024 (1992).
112

27.

E. Charafe-Jauffret, C. Tarpin, P. Viens, F. Bertucci, Defining the molecular biology of
inflammatory breast cancer. Semin Oncol 35, 41-50 (2008).

28.

A. M. Gonzalez-Angulo, G. N. Hortobagyi, F. J. Esteva, Adjuvant therapy with
trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11, 857-867 (2006).

29.

N. T. Ueno, A. U. Buzdar, S. E. Singletary, F. C. Ames, M. D. McNeese, F. A. Holmes,
R. L. Theriault, E. A. Strom, B. J. Wasaff, L. Asmar, D. Frye, G. N. Hortobagyi,
Combined-modality treatment of inflammatory breast carcinoma: twenty years of
experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol 40, 321329 (1997).

30.

F. Bertucci, N. T. Ueno, P. Finetti, P. Vermeulen, A. Lucci, F. M. Robertson, M.
Marsan, T. Iwamoto, S. Krishnamurthy, H. Masuda, P. Van Dam, W. A. Woodward, M.
Cristofanilli, J. M. Reuben, L. Dirix, P. Viens, W. F. Symmans, D. Birnbaum, S. J. Van
Laere, Gene expression profiles of inflammatory breast cancer: correlation with response
to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 25, 358-365
(2014).

31.

A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M.
Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar,
G. N. Hortobagyi, Trends for inflammatory breast cancer: is survival improving?
Oncologist 12, 904-912 (2007).

32.

H. Yamauchi, W. A. Woodward, V. Valero, R. H. Alvarez, A. Lucci, T. A. Buchholz, T.
Iwamoto, S. Krishnamurthy, W. Yang, J. M. Reuben, G. N. Hortobagyi, N. T. Ueno,
Inflammatory breast cancer: what we know and what we need to learn. Oncologist 17,
891-899 (2012).

113

33.

J. A. Niemiec, A. Adamczyk, A. Ambicka, A. Mucha-Malecka, W. M. Wysocki, B.
Biesaga, M. Ziobro, I. Cedrych, A. Grela-Wojewoda, M. Domagala-Haduch, J.
Wysocka, J. Rys, B. Sas-Korczynska, Prognostic role of lymphatic vessel density and
lymphovascular invasion in chemotherapy-naive and chemotherapy-treated patients with
invasive breast cancer. Am J Transl Res 9, 1435-1447 (2017).

34.

E. S. Steinskog, S. J. Sagstad, M. Wagner, T. V. Karlsen, N. Yang, C. E. Markhus, S.
Yndestad, H. Wiig, H. P. Eikesdal, Impaired lymphatic function accelerates cancer
growth. Oncotarget 7, 45789-45802 (2016).

35.

I. J. Suarez-Arroyo, Y. R. Feliz-Mosquea, J. Perez-Laspiur, R. Arju, S. Giashuddin, G.
Maldonado-Martinez, L. A. Cubano, R. J. Schneider, M. M. Martinez-Montemayor, The
proteome signature of the inflammatory breast cancer plasma membrane identifies novel
molecular markers of disease. Am J Cancer Res 6, 1720-1740 (2016).

36.

J. S. Tomlinson, M. L. Alpaugh, S. H. Barsky, An intact overexpressed Ecadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of
inflammatory breast carcinoma. Cancer Res 61, 5231-5241 (2001).

37.

N. Cabioglu, Y. Gong, R. Islam, K. R. Broglio, N. Sneige, A. Sahin, A. M. GonzalezAngulo, P. Morandi, C. Bucana, G. N. Hortobagyi, M. Cristofanilli, Expression of
growth factor and chemokine receptors: new insights in the biology of inflammatory
breast cancer. Ann Oncol 18, 1021-1029 (2007).

38.

S. Dawood, K. Broglio, Y. Gong, W. T. Yang, M. Cristofanilli, S. W. Kau, F. MericBernstam, T. A. Buchholz, G. N. Hortobagyi, A. M. Gonzalez-Angulo, G. Inflammatory
Breast Cancer Research, Prognostic significance of HER-2 status in women with
inflammatory breast cancer. Cancer 112, 1905-1911 (2008).

114

39.

C. G. Kleer, K. L. van Golen, S. D. Merajver, Molecular biology of breast cancer
metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants.
Breast Cancer Res 2, 423-429 (2000).

40.

J. Lee, C. Bartholomeusz, O. Mansour, J. Humphries, G. N. Hortobagyi, P. Ordentlich,
N. T. Ueno, A class I histone deacetylase inhibitor, entinostat, enhances lapatinib
efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1
expression. Breast Cancer Res Treat 146, 259-272 (2014).

41.

B. Gerber, S. Loibl, H. Eidtmann, M. Rezai, P. A. Fasching, H. Tesch, H. Eggemann, I.
Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, C. Jackisch, G. Kunz, J. U.
Blohmer, J. Huober, M. Hauschild, V. Nekljudova, M. Untch, G. von Minckwitz, I.
German Breast Group, Neoadjuvant bevacizumab and anthracycline-taxane-based
chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto
study (GBG 44). Ann Oncol 24, 2978-2984 (2013).

42.

K. D. Amos, B. Adamo, C. K. Anders, Triple-negative breast cancer: an update on
neoadjuvant clinical trials. Int J Breast Cancer 2012, 385978 (2012).

43.

K. Ha, W. Fiskus, D. S. Choi, S. Bhaskara, L. Cerchietti, S. G. Devaraj, B. Shah, S.
Sharma, J. C. Chang, A. M. Melnick, S. Hiebert, K. N. Bhalla, Histone deacetylase
inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor
and cisplatin against human triple negative breast cancer cells. Oncotarget 5, 5637-5650
(2014).

44.

I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O'Reilly, F. Natt, J.
Hall, H. A. Lane, G. Thomas, The mTOR inhibitor RAD001 sensitizes tumor cells to
DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747759 (2005).
115

45.

N. Berrada, S. Delaloge, F. Andre, Treatment of triple-negative metastatic breast cancer:
toward individualized targeted treatments or chemosensitization? Ann Oncol 21 Suppl 7,
vii30-35 (2010).

46.

J. Harding, B. Burtness, Cetuximab: an epidermal growth factor receptor chemeric
human-murine monoclonal antibody. Drugs Today (Barc) 41, 107-127 (2005).

47.

H. A. Wahba, H. A. El-Hadaad, Current approaches in treatment of triple-negative breast
cancer. Cancer Biol Med 12, 106-116 (2015).

48.

B. D. Lehmann, J. A. Pietenpol, Identification and use of biomarkers in treatment
strategies for triple-negative breast cancer subtypes. J Pathol 232, 142-150 (2014).

49.

S. J. Van Laere, N. T. Ueno, P. Finetti, P. Vermeulen, A. Lucci, F. M. Robertson, M.
Marsan, T. Iwamoto, S. Krishnamurthy, H. Masuda, P. van Dam, W. A. Woodward, P.
Viens, M. Cristofanilli, D. Birnbaum, L. Dirix, J. M. Reuben, F. Bertucci, Uncovering
the molecular secrets of inflammatory breast cancer biology: an integrated analysis of
three distinct affymetrix gene expression datasets. Clin Cancer Res 19, 4685-4696
(2013).

50.

S. F. Madden, C. Clarke, P. Gaule, S. T. Aherne, N. O'Donovan, M. Clynes, J. Crown,
W. M. Gallagher, BreastMark: an integrated approach to mining publicly available
transcriptomic datasets relating to breast cancer outcome. Breast Cancer Res 15, R52
(2013).

51.

A. H. Klopp, L. Lacerda, A. Gupta, B. G. Debeb, T. Solley, L. Li, E. Spaeth, W. Xu, X.
Zhang, M. T. Lewis, J. M. Reuben, S. Krishnamurthy, M. Ferrari, R. Gaspar, T. A.
Buchholz, M. Cristofanilli, F. Marini, M. Andreeff, W. A. Woodward, Mesenchymal
stem cells promote mammosphere formation and decrease E-cadherin in normal and
malignant breast cells. PLoS One 5, e12180 (2010).
116

52.

J. Kurebayashi, T. Otsuki, C. K. Tang, M. Kurosumi, S. Yamamoto, K. Tanaka, M.
Mochizuki, H. Nakamura, H. Sonoo, Isolation and characterization of a new human
breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.
Br J Cancer 79, 707-717 (1999).

53.

F. Ye, J. A. Bauer, J. A. Pietenpol, Y. Shyr, Analysis of high-throughput RNAi
screening data in identifying genes mediating sensitivity to chemotherapeutic drugs:
statistical approaches and perspectives. BMC Genomics 13 Suppl 8, S3 (2012).

54.

E. Sezgin, D. Waithe, J. Bernardino de la Serna, C. Eggeling, Spectral imaging to
measure heterogeneity in membrane lipid packing. Chemphyschem 16, 1387-1394
(2015).

55.

J. Folch, M. Lees, G. H. Sloane Stanley, A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 226, 497-509 (1957).

56.

Y. Y. Fan, K. S. Ramos, R. S. Chapkin, Dietary gamma-linolenic acid enhances mouse
macrophage-derived prostaglandin E1 which inhibits vascular smooth muscle cell
proliferation. J Nutr 127, 1765-1771 (1997).

57.

R. S. Chapkin, K. J. Coble, Remodeling of Mouse Kidney Phospholipid Classes and
Subclasses by Diet. J Nutr Biochem 2, 158-164 (1991).

58.

S. Pounds, S. W. Morris, Estimating the occurrence of false positives and false negatives
in microarray studies by approximating and partitioning the empirical distribution of pvalues. Bioinformatics 19, 1236-1242 (2003).

59.

A. M. Torres-Adorno, J. Lee, T. Kogawa, P. Ordentlich, D. Tripathy, B. Lim, N. T.
Ueno, Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through
NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast
Cancer. Clin Cancer Res, (2017).
117

60.

M. Mottamal, S. Zheng, T. L. Huang, G. Wang, Histone deacetylase inhibitors in clinical
studies as templates for new anticancer agents. Molecules 20, 3898-3941 (2015).

61.

A. Saito, T. Yamashita, Y. Mariko, Y. Nosaka, K. Tsuchiya, T. Ando, T. Suzuki, T.
Tsuruo, O. Nakanishi, A synthetic inhibitor of histone deacetylase, MS-27-275, with
marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96,
4592-4597 (1999).

62.

D. A. Yardley, R. R. Ismail-Khan, B. Melichar, M. Lichinitser, P. N. Munster, P. M.
Klein, S. Cruickshank, K. D. Miller, M. J. Lee, J. B. Trepel, Randomized phase II,
double-blind, placebo-controlled study of exemestane with or without entinostat in
postmenopausal women with locally recurrent or metastatic estrogen receptor-positive
breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin
Oncol 31, 2128-2135 (2013).

63.

N. N. Danial, BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin
Cancer Res 13, 7254-7263 (2007).

64.

P. Fritsche, B. Seidler, S. Schuler, A. Schnieke, M. Gottlicher, R. M. Schmid, D. Saur,
G. Schneider, HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the
BH3-only protein NOXA. Gut 58, 1399-1409 (2009).

65.

S. Inoue, J. Riley, T. W. Gant, M. J. Dyer, G. M. Cohen, Apoptosis induced by histone
deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa. Leukemia 21,
1773-1782 (2007).

66.

C. M. Goodwin, O. W. Rossanese, E. T. Olejniczak, S. W. Fesik, Myeloid cell leukemia1 is an important apoptotic survival factor in triple-negative breast cancer. Cell Death
Differ 22, 2098-2106 (2015).

118

67.

Y. Mei, W. Du, Y. Yang, M. Wu, Puma(*)Mcl-1 interaction is not sufficient to prevent
rapid degradation of Mcl-1. Oncogene 24, 7224-7237 (2005).

68.

P. E. Czabotar, E. F. Lee, M. F. van Delft, C. L. Day, B. J. Smith, D. C. Huang, W. D.
Fairlie, M. G. Hinds, P. M. Colman, Structural insights into the degradation of Mcl-1
induced by BH3 domains. Proc Natl Acad Sci U S A 104, 6217-6222 (2007).

69.

C. Ploner, R. Kofler, A. Villunger, Noxa: at the tip of the balance between life and death.
Oncogene 27 Suppl 1, S84-92 (2008).

70.

C. Mitchell, A. Yacoub, H. Hossein, A. P. Martin, M. D. Bareford, P. Eulitt, C. Yang, K.
P. Nephew, P. Dent, Inhibition of MCL-1 in breast cancer cells promotes cell death in
vitro and in vivo. Cancer Biol Ther 10, 903-917 (2010).

71.

N. Chetoui, K. Sylla, J. V. Gagnon-Houde, C. Alcaide-Loridan, D. Charron, R. AlDaccak, F. Aoudjit, Down-regulation of mcl-1 by small interfering RNA sensitizes
resistant melanoma cells to fas-mediated apoptosis. Mol Cancer Res 6, 42-52 (2008).

72.

M. Konopleva, M. Milella, P. Ruvolo, J. C. Watts, M. R. Ricciardi, B. Korchin, T.
McQueen, W. Bornmann, T. Tsao, P. Bergamo, D. H. Mak, W. Chen, J. McCubrey, A.
Tafuri, M. Andreeff, MEK inhibition enhances ABT-737-induced leukemia cell
apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL1/BIM complex. Leukemia 26, 778-787 (2012).

73.

C. Bartholomeusz, A. M. Gonzalez-Angulo, P. Liu, N. Hayashi, A. Lluch, J. FerrerLozano, G. N. Hortobagyi, High ERK protein expression levels correlate with shorter
survival in triple-negative breast cancer patients. Oncologist 17, 766-774 (2012).

74.

A. A. Adjei, R. B. Cohen, W. Franklin, C. Morris, D. Wilson, J. R. Molina, L. J. Hanson,
L. Gore, L. Chow, S. Leong, L. Maloney, G. Gordon, H. Simmons, A. Marlow, K.
Litwiler, S. Brown, G. Poch, K. Kane, J. Haney, S. G. Eckhardt, Phase I
119

pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogenactivated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with
advanced cancers. J Clin Oncol 26, 2139-2146 (2008).
75.

C. Bartholomeusz, T. Oishi, H. Saso, U. Akar, P. Liu, K. Kondo, A. Kazansky, S.
Krishnamurthy, J. Lee, F. J. Esteva, J. Kigawa, N. T. Ueno, MEK1/2 inhibitor
selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15dependent manner in a mouse xenograft model. Mol Cancer Ther 11, 360-369 (2012).

76.

K. Kim, S. Y. Kong, M. Fulciniti, X. Li, W. Song, S. Nahar, P. Burger, M. J. Rumizen,
K. Podar, D. Chauhan, T. Hideshima, N. C. Munshi, P. Richardson, A. Clark, J. Ogden,
A. Goutopoulos, L. Rastelli, K. C. Anderson, Y. T. Tai, Blockade of the MEK/ERK
signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces
pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol 149, 537-549
(2010).

77.

A. D. Awada, J.P.; Houede, N.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; Rottey, S.;
Kefford, R.; Rejeb, N.; Raymond, E., in AACR Symposium on Molecular Targets and
Cancer Therapeutics, E. Ltd., Ed. (European Journal of Cancer, 2012), vol. 48, pp. 185186.

78.

F. Catalanotti, D. B. Solit, M. P. Pulitzer, M. F. Berger, S. N. Scott, T. Iyriboz, M. E.
Lacouture, K. S. Panageas, J. D. Wolchok, R. D. Carvajal, G. K. Schwartz, N. Rosen, P.
B. Chapman, Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in
patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19, 2257-2264
(2013).

79.

J. Farley, W. E. Brady, V. Vathipadiekal, H. A. Lankes, R. Coleman, M. A. Morgan, R.
Mannel, S. D. Yamada, D. Mutch, W. H. Rodgers, M. Birrer, D. M. Gershenson,
120

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or
peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 14, 134-140 (2013).
80.

C. Bartholomeusz, X. Xie, M. K. Pitner, K. Kondo, A. Dadbin, J. Lee, H. Saso, P. D.
Smith, K. N. Dalby, N. T. Ueno, MEK Inhibitor Selumetinib (AZD6244; ARRY142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model.
Mol Cancer Ther 14, 2773-2781 (2015).

81.

L. Zhou, V. R. Ruvolo, T. McQueen, W. Chen, I. J. Samudio, O. Conneely, M.
Konopleva, M. Andreeff, HDAC inhibition by SNDX-275 (Entinostat) restores
expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of
key pro-apoptotic proteins in AML. Leukemia 27, 1358-1368 (2013).

82.

M. Baou, S. L. Kohlhaas, M. Butterworth, M. Vogler, D. Dinsdale, R. Walewska, A.
Majid, E. Eldering, M. J. Dyer, G. M. Cohen, Role of NOXA and its ubiquitination in
proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
Haematologica 95, 1510-1518 (2010).

83.

T. R. Singh, S. Shankar, R. K. Srivastava, HDAC inhibitors enhance the apoptosisinducing potential of TRAIL in breast carcinoma. Oncogene 24, 4609-4623 (2005).

84.

P. Gomez-Bougie, E. Menoret, P. Juin, C. Dousset, C. Pellat-Deceunynck, M. Amiot,
Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl1/USP9X interaction. Biochem Biophys Res Commun 413, 460-464 (2011).

85.

R. R. Rosato, J. A. Almenara, S. Grant, The histone deacetylase inhibitor MS-275
promotes differentiation or apoptosis in human leukemia cells through a process
regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Cancer Res 63, 3637-3645 (2003).

121

86.

R. L. Carpenter, H. W. Lo, Regulation of Apoptosis by HER2 in Breast Cancer. J
Carcinog Mutagen 2013, (2013).

87.

K. Milde-Langosch, A. M. Bamberger, G. Rieck, D. Grund, G. Hemminger, V. Muller,
T. Loning, Expression and prognostic relevance of activated extracellular-regulated
kinases (ERK1/2) in breast cancer. Br J Cancer 92, 2206-2215 (2005).

88.

G. Wei, A. A. Margolin, L. Haery, E. Brown, L. Cucolo, B. Julian, S. Shehata, A. L.
Kung, R. Beroukhim, T. R. Golub, Chemical genomics identifies small-molecule MCL1
repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell 21, 547-562
(2012).

89.

D. Hanahan, R. A. Weinberg, Hallmarks of cancer: the next generation. Cell 144, 646674 (2011).

90.

A. Korniluk, O. Koper, H. Kemona, V. Dymicka-Piekarska, From inflammation to
cancer. Ir J Med Sci 186, 57-62 (2017).

91.

B. Trabert, R. C. Eldridge, R. M. Pfeiffer, M. S. Shiels, T. J. Kemp, C. Guillemette, P.
Hartge, M. E. Sherman, L. A. Brinton, A. Black, A. K. Chaturvedi, A. Hildesheim, S. I.
Berndt, M. Safaeian, L. Pinto, N. Wentzensen, Prediagnostic circulating inflammation
markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer
(PLCO) screening trial. Int J Cancer 140, 600-610 (2017).

92.

R. J. Hung, C. M. Ulrich, E. L. Goode, Y. Brhane, K. Muir, A. T. Chan, L. L. Marchand,
J. Schildkraut, J. S. Witte, R. Eeles, P. Boffetta, M. R. Spitz, J. G. Poirier, D. N. Rider,
B. L. Fridley, Z. Chen, C. Haiman, F. Schumacher, D. F. Easton, M. T. Landi, P.
Brennan, R. Houlston, D. C. Christiani, J. K. Field, H. Bickeboller, A. Risch, Z. KoteJarai, F. Wiklund, H. Gronberg, S. Chanock, S. I. Berndt, P. Kraft, S. Lindstrom, A. A.
Al Olama, H. Song, C. Phelan, N. Wentzensen, U. Peters, M. L. Slattery, Gecco, T. A.
122

Sellers, Foci, G. Casey, S. B. Gruber, Corect, D. J. Hunter, Drive, C. I. Amos, B.
Henderson, G.-O. Network, Cross Cancer Genomic Investigation of Inflammation
Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal
Cancer. J Natl Cancer Inst 107, (2015).
93.

J. Todoric, L. Antonucci, M. Karin, Targeting Inflammation in Cancer Prevention and
Therapy. Cancer Prev Res (Phila) 9, 895-905 (2016).

94.

A. H. Lee, L. C. Happerfield, R. R. Millis, L. G. Bobrow, Inflammatory infiltrate in
invasive lobular and ductal carcinoma of the breast. Br J Cancer 74, 796-801 (1996).

95.

P. M. Rothwell, F. G. Fowkes, J. F. Belch, H. Ogawa, C. P. Warlow, T. W. Meade,
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual
patient data from randomised trials. Lancet 377, 31-41 (2011).

96.

E. J. Ramos, F. A. Middleton, A. Laviano, T. Sato, I. Romanova, U. N. Das, C. Chen, Y.
Qi, M. M. Meguid, Effects of omega-3 fatty acid supplementation on tumor-bearing rats.
J Am Coll Surg 199, 716-723 (2004).

97.

A. Laviano, S. Rianda, A. Molfino, F. Rossi Fanelli, Omega-3 fatty acids in cancer. Curr
Opin Clin Nutr Metab Care 16, 156-161 (2013).

98.

E. A. Brinton, R. P. Mason, Prescription omega-3 fatty acid products containing highly
purified eicosapentaenoic acid (EPA). Lipids Health Dis 16, 23 (2017).

99.

C. Vors, J. Allaire, J. Marin, M. C. Lepine, A. Charest, A. Tchernof, P. Couture, B.
Lamarche, Inflammatory gene expression in whole blood cells after EPA vs. DHA
supplementation: Results from the ComparED study. Atherosclerosis 257, 116-122
(2017).

123

100.

P. A. Corsetto, G. Montorfano, S. Zava, I. E. Jovenitti, A. Cremona, B. Berra, A. M.
Rizzo, Effects of n-3 PUFAs on breast cancer cells through their incorporation in plasma
membrane. Lipids Health Dis 10, 73 (2011).

101.

P. A. Corsetto, A. Cremona, G. Montorfano, I. E. Jovenitti, F. Orsini, P. Arosio, A. M.
Rizzo, Chemical-physical changes in cell membrane microdomains of breast cancer cells
after omega-3 PUFA incorporation. Cell Biochem Biophys 64, 45-59 (2012).

102.

C. C. Mandal, T. Ghosh-Choudhury, T. Yoneda, G. G. Choudhury, N. GhoshChoudhury, Fish oil prevents breast cancer cell metastasis to bone. Biochem Biophys Res
Commun 402, 602-607 (2010).

103.

E. B. Pasquale, Eph-ephrin bidirectional signaling in physiology and disease. Cell 133,
38-52 (2008).

104.

S. D. Funk, A. W. Orr, Ephs and ephrins resurface in inflammation, immunity, and
atherosclerosis. Pharmacol Res 67, 42-52 (2013).

105.

N. W. Gale, S. J. Holland, D. M. Valenzuela, A. Flenniken, L. Pan, T. E. Ryan, M.
Henkemeyer, K. Strebhardt, H. Hirai, D. G. Wilkinson, T. Pawson, S. Davis, G. D.
Yancopoulos, Eph receptors and ligands comprise two major specificity subclasses and
are reciprocally compartmentalized during embryogenesis. Neuron 17, 9-19 (1996).

106.

D. Arvanitis, A. Davy, Eph/ephrin signaling: networks. Genes Dev 22, 416-429 (2008).

107.

E. B. Pasquale, Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol
Cell Biol 6, 462-475 (2005).

108.

J. E. Park, A. I. Son, R. Zhou, Roles of EphA2 in Development and Disease. Genes
(Basel) 4, 334-357 (2013).

109.

M. L. Taddei, M. Parri, A. Angelucci, F. Bianchini, C. Marconi, E. Giannoni, G. Raugei,
M. Bologna, L. Calorini, P. Chiarugi, EphA2 induces metastatic growth regulating
124

amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res
9, 149-160 (2011).
110.

H. Miao, D. Q. Li, A. Mukherjee, H. Guo, A. Petty, J. Cutter, J. P. Basilion, J. Sedor, J.
Wu, D. Danielpour, A. E. Sloan, M. L. Cohen, B. Wang, EphA2 mediates liganddependent inhibition and ligand-independent promotion of cell migration and invasion
via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9-20 (2009).

111.

N. Sugiyama, E. Gucciardo, K. Lehti, EphA2 bears plasticity to tumor invasion. Cell
Cycle 12, 2927-2928 (2013).

112.

J. Huang, D. Xiao, G. Li, J. Ma, P. Chen, W. Yuan, F. Hou, J. Ge, M. Zhong, Y. Tang,
X. Xia, Z. Chen, EphA2 promotes epithelial-mesenchymal transition through the
Wnt/beta-catenin pathway in gastric cancer cells. Oncogene 33, 2737-2747 (2014).

113.

K. Salaita, P. M. Nair, R. S. Petit, R. M. Neve, D. Das, J. W. Gray, J. T. Groves,
Restriction of receptor movement alters cellular response: physical force sensing by
EphA2. Science 327, 1380-1385 (2010).

114.

E. R. Rayburn, S. J. Ezell, R. Zhang, Anti-Inflammatory Agents for Cancer Therapy.
Mol Cell Pharmacol 1, 29-43 (2009).

115.

M. J. Thun, S. J. Henley, C. Patrono, Nonsteroidal anti-inflammatory drugs as anticancer
agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94, 252-266
(2002).

116.

I. Nakazawa, M. Iwaizumi, A role of the cancer cell membrane fluidity in the cancer
metastases: an ESR study. Tohoku J Exp Med 157, 193-198 (1989).

117.

R. Zeisig, T. Koklic, B. Wiesner, I. Fichtner, M. Sentjurc, Increase in fluidity in the
membrane of MT3 breast cancer cells correlates with enhanced cell adhesion in vitro and

125

increased lung metastasis in NOD/SCID mice. Arch Biochem Biophys 459, 98-106
(2007).
118.

A. Sade, S. Tuncay, I. Cimen, F. Severcan, S. Banerjee, Celecoxib reduces fluidity and
decreases metastatic potential of colon cancer cell lines irrespective of COX-2
expression. Biosci Rep 32, 35-44 (2012).

119.

J. Wykosky, W. Debinski, The EphA2 receptor and ephrinA1 ligand in solid tumors:
function and therapeutic targeting. Mol Cancer Res 6, 1795-1806 (2008).

120.

R. M. Neve, K. Chin, J. Fridlyand, J. Yeh, F. L. Baehner, T. Fevr, L. Clark, N. Bayani, J.
P. Coppe, F. Tong, T. Speed, P. T. Spellman, S. DeVries, A. Lapuk, N. J. Wang, W. L.
Kuo, J. L. Stilwell, D. Pinkel, D. G. Albertson, F. M. Waldman, F. McCormick, R. B.
Dickson, M. D. Johnson, M. Lippman, S. Ethier, A. Gazdar, J. W. Gray, A collection of
breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer
Cell 10, 515-527 (2006).

121.

M. Y. van der Wulp, H. J. Verkade, A. K. Groen, Regulation of cholesterol homeostasis.
Mol Cell Endocrinol 368, 1-16 (2013).

122.

M. S. Jaureguiberry, M. A. Tricerri, S. A. Sanchez, G. S. Finarelli, M. A. Montanaro, E.
D. Prieto, O. J. Rimoldi, Role of plasma membrane lipid composition on cellular
homeostasis: learning from cell line models expressing fatty acid desaturases. Acta
Biochim Biophys Sin (Shanghai) 46, 273-282 (2014).

123.

W. K. Subczynski, M. Pasenkiewicz-Gierula, J. Widomska, L. Mainali, M. Raguz, High
Cholesterol/Low Cholesterol: Effects in Biological Membranes Review. Cell Biochem
Biophys, (2017).

126

124.

W. Zhao, S. Prijic, B. C. Urban, M. J. Tisza, Y. Zuo, L. Li, Z. Tan, X. Chen, S. A. Mani,
J. T. Chang, Candidate Antimetastasis Drugs Suppress the Metastatic Capacity of Breast
Cancer Cells by Reducing Membrane Fluidity. Cancer Res 76, 2037-2049 (2016).

125.

T. F. Osborne, Sterol regulatory element-binding proteins (SREBPs): key regulators of
nutritional homeostasis and insulin action. J Biol Chem 275, 32379-32382 (2000).

126.

H. Shimano, I. Shimomura, R. E. Hammer, J. Herz, J. L. Goldstein, M. S. Brown, J. D.
Horton, Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice
homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest 100, 21152124 (1997).

127.

J. D. Horton, J. L. Goldstein, M. S. Brown, SREBPs: activators of the complete program
of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 1125-1131 (2002).

128.

S. Nandi, L. Ma, M. Denis, J. Karwatsky, Z. Li, X. C. Jiang, X. Zha, ABCA1-mediated
cholesterol efflux generates microparticles in addition to HDL through processes
governed by membrane rigidity. J Lipid Res 50, 456-466 (2009).

129.

A. R. Miserez, P. Y. Muller, L. Barella, S. Barella, H. B. Staehelin, E. Leitersdorf, J. D.
Kark, Y. Friedlander, Sterol-regulatory element-binding protein (SREBP)-2 contributes
to polygenic hypercholesterolaemia. Atherosclerosis 164, 15-26 (2002).

130.

K. Ma, P. Malhotra, V. Soni, O. Hedroug, F. Annaba, A. Dudeja, L. Shen, J. R. Turner,
E. A. Khramtsova, S. Saksena, P. K. Dudeja, R. K. Gill, W. A. Alrefai, Overactivation of
intestinal SREBP2 in mice increases serum cholesterol. PLoS One 9, e84221 (2014).

131.

N. Fournier, S. Tardivel, J. F. Benoist, B. Vedie, D. Rousseau-Ralliard, M. Nowak, F.
Allaoui, J. L. Paul, Eicosapentaenoic acid membrane incorporation impairs ABCA1dependent cholesterol efflux via a protein kinase A signaling pathway in primary human
macrophages. Biochim Biophys Acta 1861, 331-341 (2016).
127

132.

Y. W. Hu, X. Ma, X. X. Li, X. H. Liu, J. Xiao, Z. C. Mo, J. Xiang, D. F. Liao, C. K.
Tang, Eicosapentaenoic acid reduces ABCA1 serine phosphorylation and impairs
ABCA1-dependent cholesterol efflux through cyclic AMP/protein kinase A signaling
pathway in THP-1 macrophage-derived foam cells. Atherosclerosis 204, e35-43 (2009).

133.

M. Makarewicz-Wujec, G. Parol, A. Parzonko, M. Kozlowska-Wojciechowska,
Supplementation with omega-3 acids after myocardial infarction and modification of
inflammatory markers in light of the patients' diet: a preliminary study. Kardiol Pol,
(2017).

134.

J. F. Ferguson, C. K. Mulvey, P. N. Patel, R. Y. Shah, J. Doveikis, W. Zhang, J. TabitaMartinez, K. Terembula, M. Eiden, A. Koulman, J. L. Griffin, N. N. Mehta, R. Shah, K.
J. Propert, W. L. Song, M. P. Reilly, Omega-3 PUFA supplementation and the response
to evoked endotoxemia in healthy volunteers. Mol Nutr Food Res 58, 601-613 (2014).

135.

D. P. Rose, J. M. Connolly, M. Coleman, Effect of omega-3 fatty acids on the
progression of metastases after the surgical excision of human breast cancer cell solid
tumors growing in nude mice. Clin Cancer Res 2, 1751-1756 (1996).

136.

O. Ciftci, A. Cetin, M. Aydin, K. Kaya, F. Oguz, Fish oil, contained in eicosapentaenoic
acid and docosahexaenoic acid, attenuates testicular and spermatological damage
induced by cisplatin in rats. Andrologia 46, 1161-1168 (2014).

137.

H. Shen, C. Rodriguez-Aguayo, R. Xu, V. Gonzalez-Villasana, J. Mai, Y. Huang, G.
Zhang, X. Guo, L. Bai, G. Qin, X. Deng, Q. Li, D. R. Erm, B. Aslan, X. Liu, J.
Sakamoto, A. Chavez-Reyes, H. D. Han, A. K. Sood, M. Ferrari, G. Lopez-Berestein,
Enhancing chemotherapy response with sustained EphA2 silencing using multistage
vector delivery. Clin Cancer Res 19, 1806-1815 (2013).

128

138.

M. J. Wagner, R. Mitra, M. J. McArthur, W. Baze, K. Barnhart, S. Wu, C. RodriguezAguayo, X. Zhang, R. L. Coleman, G. Lopez-Berestein, A. K. Sood, Preclinical
mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted
siRNA). Mol Cancer Ther, (2017).

139.

J. M. Balko, J. M. Giltnane, K. Wang, L. J. Schwarz, C. D. Young, R. S. Cook, P.
Owens, M. E. Sanders, M. G. Kuba, V. Sanchez, R. Kurupi, P. D. Moore, J. A. Pinto, F.
D. Doimi, H. Gomez, D. Horiuchi, A. Goga, B. D. Lehmann, J. A. Bauer, J. A.
Pietenpol, J. S. Ross, G. A. Palmer, R. Yelensky, M. Cronin, V. A. Miller, P. J.
Stephens, C. L. Arteaga, Molecular profiling of the residual disease of triple-negative
breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Cancer Discov 4, 232-245 (2014).

140.

P. Hauck, B. H. Chao, J. Litz, G. W. Krystal, Alterations in the Noxa/Mcl-1 axis
determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol
Cancer Ther 8, 883-892 (2009).

141.

A. R. Mattoo, J. Zhang, L. A. Espinoza, J. M. Jessup, Inhibition of NANOG/NANOGP8
downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of
BH3 mimetics. Clin Cancer Res 20, 5446-5455 (2014).

142.

V. Palve, S. Mallick, G. Ghaisas, S. Kannan, T. Teni, Overexpression of Mcl-1L splice
variant is associated with poor prognosis and chemoresistance in oral cancers. PLoS One
9, e111927 (2014).

143.

Y. Konno, P. Dong, Y. Xiong, F. Suzuki, J. Lu, M. Cai, H. Watari, T. Mitamura, M.
Hosaka, S. J. Hanley, M. Kudo, N. Sakuragi, MicroRNA-101 targets EZH2, MCL-1 and
FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive
endometrial cancer cells. Oncotarget 5, 6049-6062 (2014).
129

144.

D. L. Hermanson, S. G. Das, Y. Li, C. Xing, Overexpression of Mcl-1 confers multidrug
resistance, whereas topoisomerase IIbeta downregulation introduces mitoxantronespecific drug resistance in acute myeloid leukemia. Mol Pharmacol 84, 236-243 (2013).

145.

P. Geserick, J. Wang, M. Feoktistova, M. Leverkus, The ratio of Mcl-1 and Noxa
determines ABT737 resistance in squamous cell carcinoma of the skin. Cell Death Dis 5,
e1412 (2014).

146.

J. Yan, N. Zhong, G. Liu, K. Chen, X. Liu, L. Su, S. Singhal, Usp9x- and Noxamediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human
non-small-cell lung cancer cells. Cell Death Dis 5, e1316 (2014).

147.

D. P. Zelinski, N. D. Zantek, J. C. Stewart, A. R. Irizarry, M. S. Kinch, EphA2
overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61, 23012306 (2001).

148.

P. D. Dunne, S. Dasgupta, J. K. Blayney, D. G. McArt, K. L. Redmond, J. A. Weir, C.
A. Bradley, T. Sasazuki, S. Shirasawa, T. Wang, S. Srivastava, C. W. Ong, K. Arthur,
M. Salto-Tellez, R. H. Wilson, P. G. Johnston, S. Van Schaeybroeck, EphA2 Expression
Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal
Cancer. Clin Cancer Res 22, 230-242 (2016).

149.

M. S. Kinch, M. B. Moore, D. H. Harpole, Jr., Predictive value of the EphA2 receptor
tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9, 613-618
(2003).

150.

P. H. Thaker, M. Deavers, J. Celestino, A. Thornton, M. S. Fletcher, C. N. Landen, M. S.
Kinch, P. A. Kiener, A. K. Sood, EphA2 expression is associated with aggressive
features in ovarian carcinoma. Clin Cancer Res 10, 5145-5150 (2004).

130

151.

A. A. Kamat, D. Coffey, W. M. Merritt, E. Nugent, D. Urbauer, Y. G. Lin, C. Edwards,
R. Broaddus, R. L. Coleman, A. K. Sood, EphA2 overexpression is associated with lack
of hormone receptor expression and poor outcome in endometrial cancer. Cancer 115,
2684-2692 (2009).

152.

S. V. Mudali, B. Fu, S. S. Lakkur, M. Luo, E. E. Embuscado, C. A. Iacobuzio-Donahue,
Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma
and correlation with genetic status. Clin Exp Metastasis 23, 357-365 (2006).

153.

H. Hou, Y. Kang, Y. Li, Y. Zeng, G. Ding, J. Shang, miR-33a expression sensitizes
Lgr5+ HCC-CSCs to doxorubicin via ABCA1. Neoplasma 64, 81-91 (2017).

154.

J. L. Chou, R. L. Huang, J. Shay, L. Y. Chen, S. J. Lin, P. S. Yan, W. T. Chao, Y. H.
Lai, Y. L. Lai, T. K. Chao, C. I. Lee, C. K. Tai, S. F. Wu, K. P. Nephew, T. H. Huang,
H. C. Lai, M. W. Chan, Hypermethylation of the TGF-beta target, ABCA1 is associated
with poor prognosis in ovarian cancer patients. Clin Epigenetics 7, 1 (2015).

155.

E. L. Hedditch, B. Gao, A. J. Russell, Y. Lu, C. Emmanuel, J. Beesley, S. E. Johnatty, X.
Chen, P. Harnett, J. George, G. Australian Ovarian Cancer Study, R. T. Williams, C.
Flemming, D. Lambrechts, E. Despierre, S. Lambrechts, I. Vergote, B. Karlan, J. Lester,
S. Orsulic, C. Walsh, P. Fasching, M. W. Beckmann, A. B. Ekici, A. Hein, K. Matsuo, S.
Hosono, T. Nakanishi, Y. Yatabe, T. Pejovic, Y. Bean, F. Heitz, P. Harter, A. du Bois, I.
Schwaab, E. Hogdall, S. K. Kjaer, A. Jensen, C. Hogdall, L. Lundvall, S. A. Engelholm,
B. Brown, J. Flanagan, M. D. Metcalf, N. Siddiqui, T. Sellers, B. Fridley, J.
Cunningham, J. Schildkraut, E. Iversen, R. P. Weber, A. Berchuck, E. Goode, D. D.
Bowtell, G. Chenevix-Trench, A. deFazio, M. D. Norris, S. MacGregor, M. Haber, M. J.
Henderson, ABCA transporter gene expression and poor outcome in epithelial ovarian
cancer. J Natl Cancer Inst 106, (2014).
131

156.

L. M. McShane, D. G. Altman, W. Sauerbrei, S. E. Taube, M. Gion, G. M. Clark, N. C.
I. E. W. G. o. C. D. Statistics Subcommittee of the, REporting recommendations for
tumour MARKer prognostic studies (REMARK). Br J Cancer 93, 387-391 (2005).

157.

M. J. Pencina, A. M. Navar-Boggan, R. B. D'Agostino, Sr., K. Williams, B. Neely, A. D.
Sniderman, E. D. Peterson, Application of new cholesterol guidelines to a populationbased sample. N Engl J Med 370, 1422-1431 (2014).

158.

F. Cortese, M. Gesualdo, A. Cortese, S. Carbonara, F. Devito, A. Zito, G. Ricci, P.
Scicchitano, M. M. Ciccone, Rosuvastatin: Beyond the cholesterol-lowering effect.
Pharmacol Res 107, 1-18 (2016).

159.

S. M. Hoy, Pitavastatin: A Review in Hypercholesterolemia. Am J Cardiovasc Drugs 17,
157-168 (2017).

132

VITA

Angie Marie Torres-Adorno was born in Bayamón, Puerto Rico on October 22, 1988,
the daughter of Luis Angel Torres-Quiñones and María Magdalena Adorno-Ríos.
After completing her studies at Miguel de Cervantes Saavedra High School in
Bayamón, Puerto Rico in 2006, she entered The University of Puerto Rico at
Bayamón in Bayamón, Puerto Rico. She received the degree of Bachelor of Science
with a major in General Biology, minor in Biotechnolo gy, from the University of
Puerto Rico at Bayamón in June, 2011. In August of 2011 she entered The University
of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences to pursue her Ph.D. degree in Cancer Biology and Experimental
Therapeutics.

133

